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ABSTRACT 
Human hexokinase I catalyzes the first step in glycolysis, playing a key role in the 
energy metabolism of brain tissue. The chapters included in this thesis focus on structure-
function relationships of hexokinase I. Glucose 6-phosphate (G6P), the reaction product, 
binds to hexokinase I with apparent negative cooperativity and inhibits catalysis (Chapter II). 
Both N- and C-terminal binding sites for G6P are functional, yet only one G6P molecule 
binds to hexokinase I. 
A series of site-directed mutations were constructed in the base- and ribose-binding 
pocket of ATP in C-terminal half of hexokinase I G6P inhibition completely (Chapterlll).The 
same mutations in the context of a truncated form of hexokinase I, which contains only the 
C-terminal half of the enzyme (mini-hexokinase), do not affect G6P inhibition. Obviously, 
the effects of the same mutations in full-length and mini-hexokinase I are different. On the 
basis of these results and structural information, we propose a model for allosteric G6P 
inhibition of hexokinase I. G6P binds to N-terminal half that reaches the active site of the C-
terminal half. Furthermore, the results here suggest that the base- and ribose-binding pocket 
is the target of allosteric inhibition. 
Chapter IV investigates the conformation of hexokinase I under different ligation 
states. The interface mutant engineered for the investigation is proved to be monomeric by 
small angel x-ray scattering and x-ray crystallography. The monomeric interface mutant and 
wild-type hexokinase I have essentially identical kinetic properties, thus evidently 
dimerization plays no role in hexokinase I function under conditions of in vitro. Small angle 
x-ray scattering data are consistent with the retention of a rod-like conformation under 
different ligation states, suggesting only subtle conformational changes in response to 
different ligands. 
Chapter V reveals the ADP binding site in the C-terminal half of hexokinase I. Also, 
it suggests the location of allosteric interface between the N- and C-halves. Combining the 
structural information and kinetic results, the authors propose molecular mechanism of 
allosteric inhibition. 
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CHAPTER I. GENERAL INTRODUCTION 
Literature Review 
Hexokinase (ADP: D-hexose 6-phosphotransferase, EC 2.7.1.1) catalyses the 
conversion of glucose to glucose 6-phosphate: 
Glucose + ATPeMg —> Glucose 6-phosphate + ADP*Mg 
There are four different isoforms of mammalian hexokinase, named hexokinases I-IV (1-3). 
Hexokinase I—HI have molecular weights of 100 kDa. Hexokinase IV, however, is a 50 kDa 
protein. Amino acid sequence alignments reveal significant sequence similarity among 
different isomers. The N- and C-domain of 100 kDa hexokinases share high sequence 
homology with each other (4-5), with that of hexokinase IV. In fact, hexokianses I—in may 
have evolved from a primodial gene through gene duplication and fusion (6). 
The four isoforms also differ in their kinetic behaviors and tissue distributions. 
Hexokinases I—in are subject to potent inhibition by the reaction product G6P, while 
hexokinase IV, also called glucokinase, is not inhibited by G6P. G6P-inhibition can be 
reversed by inorganic phosphate in hexokianse I, but not in hexokinases II & ni. 
Hexokinase isomers also differ in their tissue distributions. Hexokinase I is found in almost 
all tissues, and is highly expressed in brain and red blood cells (1-3). Hexokinase II is mainly 
located in muscle and adipose tissue. Hexokinase HI is expressed in very low levels, and is 
associated with the cell nucleus. Hexokinase IV is found mainly in liver, and uses excess 
blood sugar for glycogen synthesis and other important biological syntheses. Since the 
energy source for brain tissue is glucose, and hexokinase I is one of the key enzymes in 
glycolysis, studying the regulatory mechanism of hexokinase I in vitro can provide valuable 
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information in understanding its regulatory mechanism in vivo. This thesis focuses on the 
structure-function relationships of human brain hexokinase I with emphasis on its mechanism 
of regulation. 
Physiological functions of hexokinase in brain tissue~ Brain hexokinase in vivo is 
located on the surface of the mitochondrion (7). This location permits it to directly channel 
ADP and ATP in and out of the mitochondrial matrix, where most of the ATP is synthesized. 
As proposed, this organization increases the efficiency of energy production (8, 9). 
Hexokinase I may be an oligomer when bound to mitochondria (10, 11). The state of 
oligomerization, however, is not clear (7, 11, 12). In solution hexokinase I is a monomer at 
physiological concentrations (1-10 (Jg/ml), but dimerizes when its concentration is higher 
than 1 mg/ml (12). Binding of human hexokinase I to rat liver mitochondria is cooperative 
with a Hill coefficient of 3.1 to 3.3 (7, 13, 14, 17). 
Brain tissue contains hexokinase I exclusively (15, 16). The major subcellular 
location of hexokinase I is on the outer mitochondrial membrane, and the interaction seems 
to be specific and reversible, since G6P and high physiological concentrations of ATP can 
solubilize hexokinase from mitochondria (7, 14). Purified hexokinase I can re-associate with 
mitochondria. Electron microscopy studies show that hexokinase interacts with the 
mitochondrial outer membrane, at specific areas called contact sites (18, 19, 20). The contact 
sites contain porin (VDAC) in the outer membrane, adenylate nucleotide translocator (ANT) 
in the inner membrane, and cyclophylin-D (Figure 1.1). This protein complex constitutes the 
mitochondria permeability transition pore (PTP), which putatively opens during apoptosis 
and necrosis. The possible role played by hexokinase I in this biological process (if any), 
remains to be determined. 
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Figure 1.1. Model for hexokinase I—mitochondria interaction. Hexokinase I interacts with 
porin (voltage dependent anion channel, or VDAC) in the outer membrane through its N-
terminal hydrophobic tail. In the inner mitochondrial membrane, adenulate nucleotide 
translocator (ANT) and porin form a tight junction. Cyclophylin D (Cph. D) interacts with 
ANT. ATP transported from ANT-porin is channeled to the active site of hexokinase, and 
ADP is channeled back through the same complex. BPR, benzodiapine peripheral receptor. 
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The N-terminal 10 amino acid residues of human brain hexokinase are highly 
hydrophobic. A hydrophobicity analysis predicts that the sequence is membrane associable. 
Experimental results support this prediction: Mitochondrially bound hexokinase, after partial 
proteolysis, does not re-associate with mitochondria. The amino acid sequence analysis 
shows that the partially proteolyzed protein is missing its first 10 amino acids, suggesting the 
importance of this hydrophobic tail in membrane association (19, 21, 22). Aleshin examined 
the surface potential of human hexokinase I (unpublished results). The analysis showed that 
the C-terminus of hexokinase I is positively charged, while the N-terminus is negatively 
charged (Fig. 1.2). Human and rat hexokinase I show biphasic binding to rat liver 
mitochondria, with a Hill coefficient around 3 (14, 17). Furthermore, cross-linking of 
mitochondrial bound hexokinase suggests a tetramer (11). Combining all the experimental 
data together, Aleshin, (unpublished) proposed a model for hexokinase binding to 
mitochondria, as shown in Fig. 1.3. 
Crystal structures of hexokinase /— The first crystal structure of hexokinase I (Fig. 
1.4) with bound G6P and glucose was published in 1998 by Aleshin, et al. (10) and 
confirmed by Mulichak (23). Later Aleshin et al. (5) reported the structure of the hexokinase 
complex with Glc/P{. 
In their crystal structure, hexokinase I crystallized as a dimer, with two monomers in 
a head-to-tail association with each other. A monomer of hexokinase is composed of two 
structurally homologous N and C-domains, connected by a long interdomain a-helix. Each 
domain can be subdivided into two parts: the small subdomain and the large subdomain. 
Both N and C-domain has a G6P binding site (Fig. 1.4). 
Figure 1.2. Surface potential of the hexokinase I monomer. The N-domain of hexokinase I is 
positively charged (purple). The C-domain of hexokinase I is negatively charged (red). The 
charge distribution is on the same face of hexokinase I, 
ATP 
Figure 1.3. A model of hexokinase I oligomer interacting with porin dimer. Hexokinase I 
subunits are shown in green and purple and the small subdomains are in darker green and 
purple. The N-terminal helices, which are inserted into the membrane, are blue. ADP 
molecules in the N-domain are yellow, ADP in C-terminal are red. Two possible locations of 
porin dimer are shown as concentric circles in pictures (a) and (b). Two porin molecules 
interact with each other and also with the targeting helices of hexokinase I. The model is 
consistent with either a tetramer or a dimer interacting with a porin dimer. 
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Figure 1.4. Hexokinase dimer complex with G6P/Glc. (a) Monomer of dimeric 
hexokinase I. The monomer adopts a rod-like conformation, with N- and C-domains 
connected by an interdomain a-helix. Each domain is divided into two parts: the small 
subdomain (yellow) and the large subdomain (whilte and purple). Glucose (red) and G6P 
(blue) are presented by space-filling models, (b) Interdomain contacts between hexokinase 
monomers. The three contact regions, labeled from 1 to 3, are marked in red. 
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Does the dimerization of hexokinase I in crystal structures play a role in regulating its 
activity? A triple mutation was introduced in subunit the interface of the hexokinase dimer to 
disrupt dimerization. This interface mutant was thoroughly studied by kinetics, small angle x-
ray scattering and crystallography (24, 25). The results from crystallization and small angle 
scattering show that this interface mutant is a monomer. Kinetic properties of this interface 
mutant are essentially identical to those of wild-type hexokinase. Mitochondrial binding 
experiments were also done on this mutant (unpublished results), and its binding behavior is 
similar to that of wild-type hexokinase I. Hence, we have no direct evidence suggesting the 
dimerization is important in hexokinase regulation. 
Two models of regulation of hexokinase I in solution— The first mechanism of G6P 
regulation of hexokinase activity was proposed by Fromm et al., based on kinetics (26, 27). 
G6P is a competitive inhibitor with respect to ATP (26, 27, 28, 29), a phenomenon that can 
be readily explained by ATP and G6P binding to a common site. White & Wilson (22) found 
that in solution, G6P protects the full-length enzyme and the truncated N-terminal domain 
from proteolysis, yet the inhibitor alone cannot protect the catalytic domain. Proteolysis 
studies suggest a high affinity G6P binding site at the N-terminal domain, the allosteric site, 
as proposed by Crane and Sols in 1954 (30). The isotope exchange experiment performed by 
Fromm and coworkers, as well as results obtained by other research groups, showed that G6P 
binds to hexokinase with a stoichoimetry of 1 for each hexokinase molecule (9, 27). Based 
on this result, White and Wilson (22) assigned the inhibitory site to the N-terminal domain. 
White and Wilson (22) and Zeng and Fromm (33) demonstrated independently that the 
truncated catalytic C-terminal domain retains potent G6P inhibition. Wilson, et al. (12, 22, 
31, and 32) suggested that this high affinity site for G6P at the catalytic domain is sterically 
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blocked in the full-length enzyme. One view, represented by Fromm and his coworkers, 
proposed that G6P directly inhibits hexokinase activity, on the other hand, Wilson et al. 
proposed that G6P regulates hexokinase activity by binding to an allosteric site at the N-
domain. Crystal structures of human (5) and rat (23) hexokinase did not resolve the issue. 
Both crystal structures show one G6P binding site at each of half of hexokinase I. 
In 1987 White and Wilson (34) proposed that the phosphate-binding site is located in 
the N-terminal domain. They demonstrated that phosphate protected the truncated N-terminal 
domain from proteolysis and that the G6P inhibition of the truncated C-terminal domain 
could not be reversed by P;. According to Wilson (12) phosphate directly competes with G6P 
for an overlapping site in the regulatory N-terminal domain. Fromm and coworkers 
performed kinetic studies on phosphate effects. Their results also suggested a high affinity 
phosphate-binding site at N-domain of hexokinase I. 
There are two models for G6P inhibition. G6P binds to the active site and prevents 
ATP from binding; or G6P binds to N-domain of hexokinase, and causes a long-range 
conformational change in active site that prevents ATP binding. Directed mutations of G6P 
sites (Chapter 2) was intended to address which G6P site, N-terminal site or C-terminal, is 
inhibitory. 
The work published in Chapter 2 (35) of this thesis together with mutational 
investigation of the G6P binding site in the N-terminal domain by Fang et al. (36), allowed 
these authors to conclude that in hexokinase I both G6P binding sites are functional. The 
requirement of a single molecule of G6P binding to each hexokinase molecule suggests that 
the two sites may be anti-cooperative. However, it did not exclude the possibility of a single, 
high affinity binding site for G6P at either the N- or C-domain. 
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The crystal structure of the monomeric hexokinase mutant complexed with ADP/Glc 
at the active site provided new insights. In the crystal structure published by Aleshin, et al. 
(24), the interface between N- and C- domains has high thermal parameters, suggesting high 
flexibility. Furthermore, a comparison between the G6P and ADP complex shows that 
conformational changes in a small subdomain (flexible subdomain, Figure 1.4) may be 
important to G6P inhibition. The biggest conformational change is around the base and 
ribose binding area in the ADP binding site. Mutations around this area abolished G6P 
inhibition in full-length hexokinase, while potent G6P inhibition still remains in the truncated 
C-terminal half of hexokinase I. Evidently in hexokinase I, the N-terminal half has the high 
affinity G6P binding site that causes potent inhibition. G6P binding to N domain can displace 
ATP from the active site, through conformational changes. Furthermore, G6P regulates 
hexokinase activity only when ATP binds productively to the active site. If the ATP binding 
site is damaged, G6P binding to the N-domain cannot regulate hexokinase activity. These 
results will be discussed in Chapter HI. 
Substrate Specificity of hexokinase— In 1966 when Koshland proposed the "induced-
fit" theory, he suggested that an enzyme's substrate specificity be evaluated in terms of 
binding and catalytic specificities (37). Binding specificity reflects how tightly the protein 
can bind substrates. The corresponding kinetic measurement is Km for the substrate. The 
lower the Km value, the tighter a protein binds a substrate. Catalytic specificity reflects how 
well an enzyme can catalyze a reaction. The corresponding parameter is kcai, meaning how 
many turnovers an enzyme catalyzes within one second. The higher the kcat is, the better an 
enzyme's catalytic specificity. Overall catalytic efficiency, according to Koshland, is the 
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combination of the two terms: kcal/ Km. Hence, an enzyme with extremely high kcat and low 
Km will have high efficiency. 
Mammalian hexokinase has a high specificity toward sugar, and only glucose and 
fructose can bind to hexokinase with high affinity. As to the specificity toward nucleotides, 
little is known. It is generally perceived that ATP is the best substrate for hexokinase I in 
vivo, considering high cytosolic ATP concentrations (about 1 mM). Based on crystal 
structure of hexokinase I complexed with Glc/ADP, a series of mutations have been 
introduced to the base and ribose binding pockets of the ATP site, and evaluated by kinetics. 
The crystal structure of hexokinase complexed with ADP obtained by Aleshin, et al., 
provides new insights regarding nucleotide specificity (25). A series of mutants have been 
constructed in the ATP binding pocket to abolish or severely weaken ATP binding. The 
results of the mutation in the ATP site were unexpected: In all mutant hexokinases, the 
apparent binding affinity for ATP is changed little, however, all the mutants show 
significantly lower kcat values (1-2% of wild-type value). Mutations at the phosphoryl 
binding sites of ATP show essentially the same effects (32, 33). ATP binding energy may be 
used to drive conformational changes in hexokinase. If ATP does not bind properly, it may 
not drive conformational changes in hexokinase that support effective catalysis. In this sense, 
hexokinase's specificity toward ATP is catalytic specificity. Kinetics studies performed with 
nucleotide triphosphates other than ATP support this idea. The binding affinities for ITP, 
GTP, CTP and UTP do not differ significantly from that of ATP; rather, their kcat values are 
significantly lower than that for ATP. 
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Dissertation Organization 
This dissertation contains six chapters. Chapter I is a literature review, and provides 
general information about hexokinase I. Chapter II describes a series of directed mutations, 
which probe residues in the G6P site of the C-terminal domain. These investigations, 
combined with those of Fang et al., showed that both N- and C-terminal G6P binding sites 
can bind G6P with high affinity, and cause inhibition. G6P inhibition of hexokinase activity 
may exhibit negative coopertivity, that is, one G6P molecule can bind to either the N- or C-
terminal site and cause potent inhibition, and the binding of one G6P to hexokinase prevents 
a second G6P molecule from binding. However, the work did not answer whether one G6P 
binding site, N- or C-domain, is dominant. 
Chapter III is a manuscript. Mutations also involved in ATP binding provide 
experimental support for an allosteric mechanism of regulation of hexokinase activity by 
G6P. The conclusions drawn from mutagenesis are reinforced by studies of the effects of 
G6P inhibition on hexokinase activity supported by nucleoside triphosphates other than ATP. 
Chapter IV is a paper published in Biochemistry. The paper combined results 
obtained from kinetic analysis and small angle x-ray scattering, and concluded that in 
solution, hexokinase dose not undergo significant conformational changes in different 
ligation states. I made the mutation, purified the mutant hexokinase and performed kinetic 
studies to evaluate the functional properties of the mutant. The interface mutant and wild-
type hexokinase I possess essentially identical properties. 
Chapter V is paper published in the Journal of Molecular Biology. The work was 
originated by Dr. Aleshin and me, based on the kinetic results of the Thr536—»Ala enzyme. 
The mutation abolishes G6P binding to the C-domain. I made the Thr536-*Ala in the context 
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of triple interface mutant hexokinase, purified the quadruple mutant, and studied it 
kinetically. The quadruple mutant retained wild-type hexokinase properties except for a six­
fold drop in specific activity. 
The last chapter (Chapter VI) presents general conclusions about the work presented, 
as well as plans and suggestions for future research on hexokinase. 
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CHAPTER O: DUAL MECHANISMS FOR GLUCOSE 6-PHOSPHATE 
INHIBITION OF HUMAN BRAIN HEXOKINASE 
A paper published in the Journal of Biological Chemistry1 
Xiaofeng Liu2'3, Chang Sup Kim, Feruz T. Kurbanov, Richard B. Honzatko, 
and Herbert J. Fromm4 
Running Title: Glucose 6-P Inhibition of Brain Hexokinase 
Abstract 
Brain hexokinase (HKI) is inhibited potently by its product glucose 6-phosphate 
(G6P); however, the mechanism of inhibition is unsettled. Two hypotheses have been 
proposed to account for product inhibition of HKI. In one, G6P binds to the active site (C-
terminal half of HKI) and competes directly with ATP, whereas in the alternative suggestion 
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the inhibitor binds to an allosteric site (N-terminal half of HKI), which indirectly displaces 
ATP from the active site. Single mutations within G6P binding pockets, as defined by 
crystal structures, at either the N- or C-terminal half of HKI, have no significant effect on 
G6P inhibition. On the other hand, the corresponding mutations eliminate product inhibition 
in a truncated form of HKI, consisting only of the C-terminal half of the enzyme. Only 
through combined mutations at the active and allosteric sites, using residues for which single 
mutations had little effect, was product inhibition eliminated in HKI. Evidently, potent 
inhibition of HKI by G6P can occur from both active and allosteric binding sites. 
Furthermore, kinetic data reported here, in conjunction with published equilibrium binding 
data, are consistent with inhibitory sites of comparable affinity linked by a mechanism of 
negative cooperativity. 
Introduction 
Mammals harbor four hexokinase [ATP:d-hexose ^-phosphotransferase (2.7.1.1)] 
isozymes (1-3). One of these, brain hexokinase (HKI), is putatively the pacemaker of 
glycolysis in brain tissue and the red blood cell (4). Two isozymes, HKI and skeletal muscle 
hexokinase (HKH), are bound to the outer membrane of mitochondria, and in the case of 
HKI, juxtaposed to a porin-adenylate translocator complex (5-7). Only a small fraction of 
the potential HKI activity is used in brain tissue because of low concentrations of 
intracellular glucose and potent product inhibition by glucose 6-phosphate (G6P) (8, 9). 
Although HKH and HKI are both markedly inhibited by G6P, orthophosphate (P,) reverses 
G6P inhibition of only HKI (10). In addition, P, reverses G6P-induced release of 
mitochondrially-bound HKI (5). Exactly how G6P functions as an inhibitor of HKI is 
unsettled (11, 12). Although most investigators now believe that G6P competes with ATP at 
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the active site of the enzyme (13-17), others suggest that G6P exerts its effect by binding to 
an allosteric site, topologically distinct from the active site (12, 18, 19). On the other hand, 
there seems to be general agreement regarding the kinetic mechanism of HKI as being rapid-
equilibrium Random Bi Bi (20-22). 
HKI arose putatively from the duplication and fusion of a primordial gene (23). 
Human HKI has a molecular mass of 100 kDa, composed of two structurally similar halves. 
The two halves (C-terminal and N-terminal) share significant sequence homology (24). 
Catalytic activity of the enzyme is associated with the C-terminal half of HKI (14, 15, 25, 
26), whereas the N-terminal half has a high affinity site for Pj, putatively responsible for the 
relief of G6P inhibition (14,15). Arora et al. (14) have suggested that the binding of G6P to 
this site releases HKI from mitochondria and is not involved in inhibition. 
HKI arose putatively from the duplication and fusion of a primordial gene (23). 
Human HKI has a molecular mass of 100 kDa, composed of two structurally similar halves. 
The two halves (C-terminal and N-terminal) share significant sequence homology (24). 
Catalytic activity of the enzyme is associated with the C-terminal half of HKI (14, 15, 25, 
26), whereas the N-terminal half has a high affinity site for P,, putatively responsible for the 
relief of G6P inhibition (14,15). 
Recently published three-dimensional structures of human (27-29) and rat (30) HKI 
by x-ray crystallography reveals two globular halves held together by a connecting helix and 
a few hydrogen bonds. Each half is structurally similar to yeast hexokinase. In addition, the 
crystal structures revealed binding sites for G6P (28,30) and P, (27). G6P binds to almost 
identical pockets at the C- and N-terminal halves of HKI, whereas the functional P,- site 
overlaps the 6-phosphoryl binding locus for G6P at the N-terminal half. Kinetic studies 
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indicate the presence of both high- and low-affinity binding sites for G6P on HKI (31). 
Presented here are the kinetic properties of several mutant forms of HKI, in which specific 
residues (individually and in combination) at G6P pockets are altered. The results support 
the following model: (i) G6P-binding to high affinity sites at either the N- or C-terminal 
pocket can independently cause potent inhibition of HKI. (ii) G6P-binding to HKI must be 
strongly anti-cooperative. 
Experimental Procedures 
Materials—A full-length cDNA of human brain hexokinase, cloned into an expression 
vector pET-1 la (from Novagen) to produce pET-1 la-HKI and pET-1 ld-miniHK, was 
available for use from a previous study (32,33). The Transformer site-directed mutagenesis 
kit is from Clonetech Laboratories, Inc. T4 polynucleotide kinase and all the restriction 
enzymes are from Promega. Bio-gel hydroxyapatite resin is from Bio-Rad. Toyopearl 
DEAE-650M is from Tosohaas. Oligonucleotide synthesis and DNA sequencing were done 
at the Iowa State University Nucleic Acid Facility. Escherichia coli strain ZSC13 (DE3), 
which does not contain endogenous hexokinase, was a gift from the Genetic Stock Center, 
Yale University. ATP, NADP, 1,5-Anhydro-D-sorbitol, deoxyribonuclease (DNAase I), 
leupeptin, PMSF, and ampicilin are from Sigma. Glucose 6-phosphate dehydrogenase came 
from Boehinger Manheim. IPTG is from BioWorld. 
Construction of Mutant Hexokinase genes— The hexokinase gene was mutated 
according to the protocols of the Clontech Transformer site-directed mutagenesis kit. The 
mutant plasmid was selected from wild-type plasmids by switching a unique Nrul restriction 
site on the pET-11 vector to another unique Xhol site for the single point mutations. Double 
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mutants were constructed by performing another single mutation existing in single-mutant 
plasmids. The primers for site-directed mutagenesis are 
5 '-GATCTTGGAGGAGCAAATTTCCGTG-3 ' for Thr536->Ala, 
5 ' -CTGGATCTTGGTTACTCTTCCTTTCGAATTC-3 ' for Gly87-»Tyr, 
5 '-CTGTGGGAGTGGÇAGGGACACTCTAC-3 ' for Asp86I->Ala, 
5 '-CTGATCATCGGCGÇTGGCACCAATGC-3 ' for Thr^_>Ala, and 
5' -CTT GGCCCT GGCT CTTGG AGG AACC-3 ' for Asp532->Ala, 
where the modified codons are in bold typeface and underlined. 
The oligonucleotide primers used for the selection of the mutant plasmid from the wild-type 
plasmid are: 
5'-CAGCCTCGCCTCGAGAACGCCAGCAAG-3\ for the conversion from the Nrul site 
to the Xhol site, and 5 ' -CCTCGCGTCGÇGAACGCCAGCAAG-3 ', for the conversion 
from the Xhol site back to the Nrul site. Mutations were confirmed by sequencing the entire 
cDNA insert, coding for HKI. 
Expression and purification of wild-type and mutant hexokinase— Transformed E. 
coli strain ZSC13, containing wild-type or mutant pET-1 la-HKI, were grown in LB media at 
37°C to an ODeoo of 0.6, whereupon the temperature was reduced to 22°C and IPTG added to 
a final concentration of 0.4 mM. Sixteen to 24 hours after induction, the cells were harvested 
and then re-suspended in 25 mM potassium phosphate (KP,-) (pH7.5), 2 mM glucose, 1 mM 
EDTA, 0.4 mM 2-mercaptoethanol, 1 mM PMSF, and 3000 units of DNAase I at a 
temperature of 4C. The cells were broken using a French press and centrifuged, after which 
the supernatant fluid was passed through a DEAE column, using a KPj-buffered (pH 7.5), 
KC1 gradient from 0 to 0.5 M. The fractions containing HKI activity were concentrated and 
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then passed though a hydroxyapatite column using a KP; (pH 7.5) gradient from 20 to 500 
mM. Pooled fractions of HKI were further purified by preparative DEAE-HPLC, as 
described elsewhere (31). 
Preparation of 1,5-anhydroglucitol 6-phosphate— AnG6P was prepared as 
described elsewhere (34). 
Treatment of glucose 6-phosphate dehydrogenase— Commercial glucose 6-
phosphate dehydrogenase comes as an ammonium sulfate precipitate. Sulfate anion mimics 
the effect of P, -relief of G6P inhibition (26). Thus, in order to avoid interference from 
sulfate, glucose 6-phosphate dehydrogenase was dialyzed against the activity assay buffer 
prior to use in kinetic experiments. 
The HKI activity assay and kinetic studies— HKI activity was determined by the 
glucose 6-phosphate dehydrogenase coupled spectrometric assay (13). Hexokinase 
concentrations were determined by Bradford assays using bovine serum albumin as a 
standard (35). Initial rate data were analyzed by using a computer program written in 
MINITAB with an a-value of 2.0 (36). In experiments with AnG6P the kinetic data were fit 
to a model for nonlinear competitive inhibition with respect to ATP, in which two molecules 
of inhibitor interact sequentially with HKI (29). This model, which hereafter we will call the 
stoichiometric model, can be used to evaluate either a system with two independent inhibitor 
sites or a system with two inhibitor sites, coupled by a mechanism of anti-cooperatively. The 
equilibrium constants for the dissociation of the first inhibitor molecule from HKI (Kj) and 
the second inhibitor molecule (Kn) take on significantly different meanings in relation to site-
specific affinity constants, as discussed below. 
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Circular dichroism (CD) spectra—CD spectra were measured from 200 to 260 nm at 
room temperature by using a Jasco J710 CD spectrometer. The concentration of HKI used 
for CD measurements was 0.2 mg/ml in a buffer containing 2mM Hepes (pH 7.8), 0.2 mM 
glucose, and 0.2 mM (3-mercaptoethanol. 
Results 
In previous work (31) we mutated residues at the putative allosteric G6P pocket and 
found only a modest change (two-fold or less) in the K-, for G6P. Subsequently, Sebastian et 
al. (37) mutated the same residues at this site, and obtained similar results, but concluded that 
this site was the high-affinity binding site for G6P responsible for HKI inhibition. The 
results from both studies are summarized in Table I. In light of these divergent conclusions, 
we examined the functional consequences of mutations at the G6P-binding site at the C-
terminal half of HKI. Our findings and conclusions are the subject of this report. 
Purity of wild- type and mutant hexokinases— The purity of wild-type and mutant 
hexokinases was greater than 95% as judged by SDS-polyacrylamide gel electrophoresis 
(data not shown). 
Secondary structure analysis— Circular dichroism spectra of mutant hexokinases and 
their cognate, wild-type forms, are essentially identical (data not shown), indicating no 
significant disruption of secondary structure or protein folding due to mutations. 
Kinetic analysis of wild-type and mutant enzymes—The results in Tables I-IH come 
from double reciprocal plots of reciprocal initial velocity versus reciprocal substrate 
concentration (data not shown). The data were subjected to goodness-of-fit analysis (36) 
using a variety of kinetic models. In all cases the G6P analog, AnG6P, which mimics the 
properties of G6P in assays of HKI (34), is a competitive inhibitor with respect to ATP and a 
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noncompetitive inhibitor relative to glucose. Kinetic parameters were obtained from the 
best-fit models, which registered goodness-of-fit values below 5%. 
Rationale for the selection of mutants—Fig. 1 illustrates the structure of HKI 
with G6P bound at the active and allosteric sites. The illustration is based on a 1.9 Â 
resolution structure of a HKI monomer, which will be presented in detail elsewhere. Asp532 
of the C-terminal half interacts with the 2-hydroxyl group of G6P, whereas Asp84, the residue 
in the N-half corresponding to Asp532, also interacts with the 2-hydroxy group of G6P. 
Asp861 and Thr680, residues of the C-half, interact with the l-hydroxyl group and 2-hydroxyl 
of G6P, respectively. Thr232 interacts with the 6-phosphoryl group of G6P in the N-terminal 
half of HKI and corresponds structurally to Thr680 of the C-terminal half. Ser88 of the N-
terminal half corresponds to Thr536 of the C-terminal half, which hydrogen bonds to the 6-
phosphoryl group of G6P. Gly87 of the N-terminal half can accommodate a mutation to a 
bulky side chain, which should block the binding of P; or G6P, as noted previously (31). 
Shown in Tables I-HI are the results from single mutations of HKI and a form of HKI in 
which the N-terminal half is absent due to a truncation of the gene which codes for HKI. 
Hereafter we will refer to this truncated form of HKI as mini-HKI. Single mutations in HKI, 
either at the allosteric site (Table I) or the G6P binding locus at the active site (Table II) 
generally cause modest increases (two fold or less) in the K, for G6P. On the other hand, the 
same mutations, when made in the putative binding locus of G6P at the active site of mini-
HKI, eliminates G6P inhibition (Table III). These results prompted a series of double 
mutations in HKI, which altered one residue in each of two G6P-binding sites (combined N-
and C-terminal half mutations). The results of these experiments are in Table III. Evidently, 
elimination of G6P-inhibition comes about only as a consequence of mutations at both G6P-
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C-half 
Figure 1. Structure of a monomeric interface mutant of hexokinase I. G6P molecules are in 
dark gray. The illustration was drawn by MOLSCRIPT (47). 
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binding sites. Evidently, both of the G6P binding sites (allosteric and active) are functional 
in HKI, and G6P-binding to either causes potent inhibition. 
Discussion 
In 1951 Weil-Mahlerbe and Bone (38) reported that G6P is a noncompetitive inhibitor with 
respect to ATP in the HKI reaction. This finding, along with the high level of G6P 
specificity when compared to that of mannose 6-phosphate and fructose 6- phosphate, led 
Crane and Sols (18) to suggest that G6P binds to a site other than the active site, i.e., an 
allosteric locus. This view has been championed by other investigators (19), notably Wilson 
(12). On the other hand, kinetic studies from our laboratory (13), as well as many others (2, 
21, 22, 39-41), showed that G6P is a competitive inhibitor with respect to ATP and a 
noncompetitive inhibitor with respect to glucose. Based upon these observations, we 
suggested that G6P competes with ATP at the active site, which is precisely what one would 
expect of a product inhibitor in a rapid-equilibrium Random Bi Bi kinetic mechanism. In 
support of the above were the findings of Sols (19), subsequently confirmed by Solheim and 
Fromm (42), that the kinetics of the reverse HKI reaction are normal Michaelin with a Km for 
G6P nearly equal to the Ki for G6P in the forward reaction. 
A major breakthrough in HKI research occurred when White and Wilson (25) cleaved 
the enzyme by proteolysis into polypeptides of nearly equal mass. Kinetic studies by these 
investigators (26), and subsequently by others (14,15), demonstrated that the C-terminal half 
of the enzyme contains the active site, whereas the N-terminal half of HKI is inactive. In 
addition, except for the reversal of G6P inhibition by P,-, the C-terminal half retained all of 
the kinetic properties of HKI (14,15,26). Hence, many investigators assigned the site for 
G6P inhibition to the C-terminal half (active site) and the site for P; relief of G6P inhibition 
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Table I. Kinetic parameters for mutations in the N-terminal half of hexokinase I 
Enzyme ^cat „ AT? •ft-m v '^c •"•m j^;AnU6P 
(Sec1 ) (mM) (P-M) (pM) 
Wild-type HKI 61.2±0.9 0.4460.07 4162 1862 
Asp84-*Alaa 63.663.0 0.68±0.04 5361 3762 
Gly87—>Tyra 57.265.5 0.7960.07 5061 6162 
Ser88—>Alaa 72.364.3 0.5960.02 4962 4662 
Thr232—>Alaa 70.161.8 0.8160.06 4262 8465 
Asp84->Alab N.P.C 0.43^0.07 3562 3362 
Asp84—»Glub N.P.C 0.4760.07 3566 1861 
Asp84->Lysb N.P.C 0.4460.05 3763 2863 
Table I footnotes. 
a Taken from (31). Data were fit to a model for simple competitive inhibition: 
1/v = l/Vm[\ + Ks/S(l + I/K-)] (Eq. 1) 
v is the velocity, Vm is the maximal velocity, Ks is the Michael is constant for ATP, and Ki is 
the inhibition constant for AnG6P. ATP is competitive versus AnG6P. 
b Taken from (37). Data were fit to a model for competitive inhibition with equation shown 
above (Eq. I). 
c The wild-type and mutant hexokinases used in the kinetic experiments (37) were not 
purified. 
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Table IL Kinetic parameters for mutations in the C-terminal half of hexokinase I 
Enzyme Specific Activity kaxt (Sec1 ) r ATP J\.m TS- Glc ^rAnG6P 
(units/mg protein/min) (mM ) (pM) (pM) 
Wild-type HKIa 61.2±0.9 10262 0.4460.07 4162 1862 
Thr536—»Alaa 5.8±0.05 9.760.08 1.8060.06 4361 2562 
Asp86I->Alaa 1.960.1 3.260.2 0.9360.13 3262. 2963 
Asp532—»Lysb Not Available0 0.029 0.5760.06 7166 2569 
Thr680->Valb Not Available0 0.013 0.2760.04 3364 45611 
Table II footnote. 
a Determined from experiments, which systematically vary the concentration of ATP and 
AnG6P. Concentrations of ATP vary from 1/3 to 3 times KmATP. Concentrations of AnG6P 
are 0, 1,2, 3, and 4 times £'iAnG6p. All glucose concentrations are fixed at 2 mM. Mg2+ 
concentrations are 3 mM above those for ATP. Data are fit to a model for simple 
competitive inhibition (Eq. 1, see Table I legend). 
b Taken from (48). 
c The specific activity is not reported. 
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Table m. G6P binding site mutations in mini-hexokinase and combined mutations 
in both N- and C- halves of hexokinase I 
Enzyme Specific kCat tr ÀTii -t-m rr Glc "~m ^AnG6r 
Activity (Sec'1 ) (mM) (pM) ((J-M) 
(units/mg 
protein/min) 
Mini-HKI, Wild-typea 5561 45.660.9 0.5060.12 5264 2562 
Mini-HKI, Thr536—• Ala3 13.262 1161 0.3760.03 5763 N.D.b 
Mini-HKI, Asp861-»Ala3 6.4±0.3 5.360.3 0.8560.02 7362 N.D.b 
Mini-HKI, Asp532-*Ala3 9.560.6 7.960.5 0.3660.08 3863 N.D.b 
Thr232_)Ala/Thr536~>Alaa 10.460.4 17.360.7 0.9060.03 6165 N.D.b 
Gly87—»T yr/Thr536—•Ala3'b 3.260.1 5.460.2 1.0860.06 10868 N.D.b 
Table III footnotes. 
3 mini-HKI is the truncated C-terminal half of hexokinase I, residues 455—917 of 
hexokinase I. 
b No inhibition by AnG6P for concentrations up to 500 (J.M. 
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to the N-terminal half (14,15). Our laboratory had suggested in 1975 that P; binds at an 
allosteric site on HKI (43). 
The three dimensional structures of human HKI yielded an unexpected result in that 
G6P was bound to both the N- and the C-terminal halves of the enzyme (28,30). Earlier 
studies indicated the binding of only a single molecule of G6P to HKI (43-45). Subsequently, 
Fang et al. (31) showed that mutations in the G6P binding site of the N-terminal half of HKI 
caused only modest increases in the K,- for G6P (Table I), and concluded that the N-terminal 
half could not be the site of potent G6P-inhibition. Shortly thereafter, Sebastian et al. (37), 
using recombinant rat HKI from COS cells, obtained similar results due to mutations of the 
G6P pocket of the N-terminal half of HKI (Table I); however, they concluded that the N-
terminal site was indeed responsible for the potent inhibition of HKI by G6P. 
The mechanism in Scheme I 
was used in the analysis of kinetic results obtained here ana in a previous study (31). The 
rate equation for Scheme I is: 
where I and S represent G6P and ATP, respectively (glucose is saturating and does not 
appear in Scheme I or in Eq. 1), Vm is the maximal velocity, Ks is the Michaelis constant for 
ATP, and K,- and Ku are inhibition constants for the binding of the first and second molecules 
of G6P, respectively. Scheme I is equally valid for the interpretation of kinetic data for 
inhibitor binding at independent sites with different affinities or for inhibitor binding to sites 
with identical affinities coupled by a mechanism of negative cooperativity. However, the 
Scheme I 
- = 1 + ^ - 1 + —+ 
v  V  f f ' f j  (1) 
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relationship of Kt- and K„ to site affinity constants is model dependent. Most importantly, K,-
does not have the same meaning for the wild-type and single-mutant enzymes. 
The results of Tables I— III are readily explained from the kinetic equation obtained 
from Scheme II: 
Scheme II differs from Scheme I in that it explicitly defines binding sites for G6P at 
the N- and C-terminal halves of HKI. Site-specific constants for the dissociation of G6P 
from the N- and C-terminal halves are represented by K„ and Kc, respectively. These 
constants measure the dissociation of G6P from the either the N-terminal half or the C-
terminal half, whichever applies, when the alternative site in not occupied by G6P. Knc 
represents the dissociation of G6P from the C-terminal site, when the N-terminal site is 
occupied by another molecule of G6P, and Kcn represents the dissociation of G6P from the 
N-terminal site, when the C-terminal site is occupied. Inhibitor- binding to the two sites is 
rapid-equilibrium, random. Hence, if one site is impaired by mutation, inhibition occurs by 
way of the other site. 
Direct comparison of the kinetic equations based on Scheme I and Scheme II results 
in the following relationship: 
(2) 
v Vm si K % w 
Scheme II 
1 (3) 
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For single mutants of HKI considered here, either Kn or Kc approaches infinity. 
Hence, Eq. 3 for single mutants reduces to AT, = K„ or AT,- - ATC, whichever applies. For the 
wild-type enzyme, however, AT„ and Kc are related to AT, (which is the kinetic constant 
reported in Tables I-III) through Eq. 3. For wild-type HKI it is not possible to extract unique 
values for Kn and Kc from kinetically determined AT,- values, unless an additional assumption 
is made. If we assume in the wild-type enzyme that AT„ and ATC are equal, a reasonable 
assumption given the AT,- values in Tables I and II, then AT„ = ATC = 2AT,-. Hence, the 
approximate twofold increase in K[ due to the mutation of one of the two G6P-binding sites is 
an expected result, and does not suggest the dominance of G6P-inhibition derived from the 
N-terminal site, as some have suggested (37). 
Other than the above subtlety, Scheme II is relatively straightforward. The binding of 
I (G6P) occurs at two sites, one in the C-terminal and the other in the N-terminal half of HKI. 
As binding constants, obtained from kinetics for either HKI or mini-HKI (Tables I—HI) are 
similar, Eq. (2) predicts no single mutation will alter the kinetics of inhibition appreciably in 
the full-length enzyme. On the other hand, a single mutation in mini-HKI or a double 
mutation in the full-length enzyme should eliminate inhibition, as has been observed (Tables 
II and III). Furthermore, on the basis of Eqs. (1) and (2), mutations made either in the C- or 
N-terminal half of HKI should effectively eliminate the (T)2 term. 
Although kinetic (31) and structural studies (27, 28, 30) strongly suggest that there 
are two binding sites on HKI for G6P and glucose, direct binding experiments implicate a 
stoichiometry of 1.0 for these ligands (43-45). These seemingly divergent findings can be 
rationalized by assuming a mechanism of negative cooperativity in ligand binding. The 
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kinetic studies of Fang et al. (31) revealed both weak and strong binding sites for G6P. 
Fractional saturation (Y) is related to G6P concentration (I) as follows: 
K{(I) + K2(I) + 2K3(I)2  
?= (4), 
I + K^I) + K2(I) + K2{I)2  
where AT/ and AT? represent association constants for ligand-binding to free HKI and K3 is the 
product of association constants which represents the binding of two molecules of G6P to 
HKI. If negative cooperativity pertains, then ATj « AT/, AT2 and 
Kx{I)+K2{_I) K(J) 
Y (5), 
\ + KX(J) + K2(J) 1 +K(I) 
where K is the sum of constants AT/ and A3. Eq. (5) represents a binding isotherm with a 
stoichiometry of unity. 
Independent binding of G6P to the active and the allosteric sites of HKI causes potent 
inhibition of HKI in vitro. HKI in vivo, however, is bound to the outer mitochondrial 
membrane. If as Arora et al. (14) suggest, the role of bound G6P at the allosteric site is to 
release HKI from the mitochondria, then G6P should not be bound to the allosteric site of 
mitochondrially-associated HKI. Under these physiological conditions, if G6P inhibition 
occurs, it will most likely occur at the active site. This observation is bolstered by recent 
work of Ardehali et al. (46), which reports G6P levels above 1 mM in perfused rat hearts, 
even though hexokinase II, present in that tissue is inhibited in vitro by G6P at micromolar 
levels. G6P binds with high affinity to the isolated N-terminal half of HKII and low affinity 
to the isolated C-terminal half, but in the full-length enzyme, high affinity inhibition 
dominates. These authors speculate, that HKH in its mitochondrially-associated state is 
inhibited weakly by G6P, and that interactions between its N- and C-terminal halves, which 
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are putatively responsible for potent G6P inhibition, are absent. In the case of HKI a fail-safe 
mechanism exists with respect to G6P inhibition, if one mode of G6P inhibition is lost, then 
the other mode remains, which assures virtually no diminution in G6P inhibition. 
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Abstract 
Crystal structures of hexokinase I implicate conformational changes near the ribose-
and base-binding pockets of ATP in a proposed mechanism of allosteric inhibition of 
catalysis by glucose 6-phosphate. Mutations of Thr784 and Leu867of the putative ATP pocket 
significantly reduce catalytic activity in both full-length hexokinase I and its truncated, C-
terminal half. The same mutations of the full-length enzyme also abolish product inhibition 
(measured as inhibition by 1,5-anhydroglucitol 6-phosphate), but have little or no effect on 
product inhibition of the truncated, C-terminal half. 1,5-Anhydroglucitol 6-phosphate is less 
effective or completely ineffective as an inhibitor of full-length hexokinase I, using GTP, 
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ITP, CTP or UTP as substrates in place of ATP, but inhibits catalysis by the truncated, C-
terminal half, using the same substrates. For nucleoside triphosphates other than ATP, Km 
values are approximately 2-8 mM, implicating a common mode of" substrate recognition that 
may involve only the polyphosphoryl moiety of the nucleotide. Thae above strongly infers 
different molecular mechanisms of product inhibition for full-Iengtrh hexokinase I and its 
truncated, C-terminal half. Product inhibition of the latter is probalbly due to the direct 
binding of glucose 6-phosphate to the active site, whereas inhibition of the full-length 
enzyme is most likely by way of an allosteric mechanism. 
Introduction 
Hexokinase (ATP: D-hexose 6-phosphate transferase, EC 2-7.1.1) catalyzes the first 
step in glycolysis: the ATP-dependent phosphorylation of glucose tto glucose 6-phosphate 
(G6P)1. Mammals possess four isozymes of hexokinase, the expression of which varies with 
tissue type (1-3). Hexokinase I is the predominant isozyme in braim tissue, binding to the 
outer membrane of mitochondria (4), where it putatively interacts with permeability 
transition pores composed of porin and adenylate nucleotide translocase (5-7). ATP, Mg2+, 
Pi and G6P influence the association of hexokinase I with mitochondria (8,3). In fact, 
hexokinase I may use permeability transition pores to directly exchange ADP/ATP with the 
inner matrix of the mitochondrion (9-10). 
Mammalian hexokinases I-HI have Mr of 100 kDa, approximately twice the mass of 
yeast hexokinase and mammalian hexokinase IV (glucokinase). The 100 kDa hexokinases 
evolved putatively by the duplication and fusion of a primordial geme (11-14). The N- and 
C-terminal halves of the 100 kDa hexokinases are homologous to each other and to 50 kDa 
hexokinases. Both domains of hexokinase II phosphorylate glucose, whereas the N-terminal 
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halves of hexokinases I and III have no catalytic function (15-16). 
Ligand-binding sites in crystallographic structures of hexokinases are primarily at a 
cleft between small and large folding domains of the polypeptide chain (17-24). The ex­
terminai half of full-length hexokinase I binds glucose to the cleft. ADP, G6P and P, bind to 
a set of overlapping sites in proximity to the bound glucose molecule. The N-terminal half 
also binds glucose at a site essentially identical to that of the C-terminal half. G6P and P; 
bind to overlapping sites of the N-terminal half, near the glucose molecule, but adenine 
nucleotides do not bind to the G6P/P,-pocket of the N-terminal half. Instead adenine 
nucleotides bind at a distinct locus near the N-terminus of the enzyme (21,22). The 
functional role of this alternative adenine nucleotide site is unclear. 
Inhibition of hexokinase I by G6P is competitive with respect to ATP (25). Product 
inhibition (both the kinetic mechanism and binding affinity) is unaltered by the truncation of 
the N-terminal half from hexokinase I (15,26,27). At low concentrations, P; relieves product 
inhibition of hexokinase I, but only if the P,-/G6P binding site of the N-terminal half is 
available or functional (28,29). G6P and P,- are mutually exclusive in binding to hexokinase I 
(30). At elevated concentrations (above 10 mM), P; is an inhibitor of catalysis (30), 
presumably binding directly to the active site of the C-terminal half. 
In spite of the wealth of data regarding G6P-ligation of hexokinase I, the molecular 
mechanism of product inhibition remains unsettled. In fact, investigators have proposed at 
least three different mechanisms: (z) G6P binds only to the active site of the C-terminal half 
and is displaced by the binding of P,- to the N-terminal half (30). (z'z) G6P only binds to the 
N-terminal half, inhibiting catalysis by way of an allosteric mechanism (31). P; relieves 
inhibition by directly displacing G6P from the N-terminal half, (z'z'z) G6P binds to both the C-
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and N-terminal halves, but the binding is anti-cooperative (32). P; blocks G6P from the N-
terminal half and stabilizes a conformational state of hexokinase I that also blocks G6P from 
the C-terminal half. Each of the proposed schemes faces a similar challenge in allowing only 
one tightly bound molecule of G6P for each molecule of hexokinase I (33-35). 
The strongest evidence in favor of model i above is the absence of any change in the 
affinity constant for G6P or the kinetic mechanism of inhibition in response to the truncation 
of the N-terminal half from the full-length enzyme (15,26,27). Presented below are the first 
single mutations of full-length hexokinase I that completely eliminate product inhibition. 
The mutations target residues of the base/ribose pocket of ATP, and are distant from the G6P 
binding pocket of the C-terminal half. Indeed, the same mutations have little effect on 
product inhibition of the truncated, C-terminal half of hexokinase I. Along with other results 
reported here, the above infers a different molecular mechanism for product inhibition of 
full-length and truncated forms of hexokinase I. The most likely mode of inhibition for the 
truncated C-terminal half is the direct competition of G6P with ATP for the active site, 
whereas for the full-length enzyme competition between G6P and ATP is most likely by way 
of an allosteric mechanism. 
Experimental 
Materials— cDNA for full-length human hexokinase, cloned into expression vector 
pET-1 la (from Novagen) to produce pET-1 la-HKI, was available from previous studies 
(29,32). Digestion of the cDNA for the full-length enzyme with restriction endonucleases 
Ncol and Bam HI produced a cDNA fragment for the C-terminal half of hexokinase I, which 
was cloned into pET-1 Id (Novagen) to create pET-1 ld-miniHKI (28,32). The Transformer 
site-directed mutagenesis kit is from Clonetech Laboratories, Inc. T4 polynucleotide kinase 
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and all restriction enzymes are from Promega. Bio-gel hydroxyapatite resin is from Bio-Rad. 
Toyopearl DEAE-650M is from Tosohaas. Oligonucleotide synthesis and. DNA sequencing 
were done at the Iowa State University Nucleic Acid Facility. Escherichia, coli strain ZSC13 
(DE3), which does not contain endogenous hexokinase, was a gift from the Genetic Stock 
Center, Yale University. ATP, GTP, UTP, CTP, NADP, 1,5-Anhydro-D-sorbitol, 
deoxyribonuclease (DNAase I), leupeptin, phenylmethylsulfonyl fluoride <PMSF), and 
ampicillin were from Sigma. Glucose 6-phosphate dehydrogenase came from Boehinger 
Manheim. Isopropyl-1 -thio-P-D-galactopyranoside (IPTG) came from BioWorld. 
Construction of Mutant Hexokinase Genes—The hexokinase gene was mutated 
according to protocols from the Clontech Transformer site-directed mutagenesis kit. The 
primers for site-directed mutagenesis were as follows: 
S '-GGCATCTTTGAGGCGAAGTTTCTCTCTC-3 ' for Thr784^Ala; 
5 ' -GGCATCTTTGAGCTGAAGTTTCTCTCTC-3 ' for Thr784->Leu; 
5 ' -GGGACACTCTACAAGGCTCATCCACACTTCTCC-3 ' for Leu867->Ala; 
5 ' -GGGACACTCTACAAGTACCATCCACACTTCTCC-3 ' for Eeu867-*Tyr. 
Modified codons in the list above are underlined and in bold typeface. Mutant plasmid were 
selected from xvild-type plasmids by changing a unique Nrul restriction site on the pET-11 
vector to a unique Xhol site for the single point mutations. The oligonucleotide selection 
primer was 5 '-CAGCCTCGCÇTÇGAGAACGCCAGCAAG-3 ' (modified bases underlined 
in bold typeface). All mutations were confirmed by sequencing the entire cDNA insert, 
coding for hexokinase I. 
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Expression and purification of wild-type and mutant hexokinase—Transformed E. 
coli strain ZSC13, containing wild-type or mutant pET-1 la-HKI, were grown in LB media at 
37° C to an ODeoo of 0.6, whereupon the temperature was reduced to 22° C and IPTG added 
to a final concentration of 0.4 mM. Sixteen to 24 hours after induction, the cells were 
harvested and then re-suspended in 25 mM KP; (pH 7.5), 2 mM glucose, 1 mM EDTA, 0.4 
mM 2-mercaptoethanol, 1 mM PMSF, and 3000 units of DNAase lata temperature of 4° C. 
Cells were disrupted by use of a French press. After centrifugation the supernatant fluid was 
passed through a DEAE column, using a KPj-buffered (pH 7.5), KCI gradient from 0 to 0.5 
M. The fractions containing hexokinase I were concentrated and then passed though a 
hydroxyapatite column using KP; (pH 7.5) gradient from 20-500 mM. Pooled fractions of 
hexokinase I were further purified by preparative DEAE-HPLC, as described elsewhere (17). 
Expression and purification of the truncated C-terminal half followed the same procedure. 
Preparation of 1,5-anhydroglucitol 6-phosphate (AnG6P)—AnG6P was prepared 
as described elsewhere (36). AnG6P has properties of inhibition and binding to hexokinase I 
that are indistinguishable from those of G6P. The coupling enzyme, glucose 6-phosphate 
dehydrogenase, used in kinetics assays of hexokinase I (see below) does not recognize 
AnG6P as a substrate. 
Treatment of glucose 6-phosphate dehydrogenase— Commercial glucose 6-
phosphate dehydrogenase comes as an ammonium sulfate precipitate. Sulfate anion mimics 
Pj-relief of G6P inhibition (15). Thus, in order to avoid interference from sulfate, glucose 6-
phosphate dehydrogenase was dialyzed against the activity assay buffer (see below) prior to 
use in kinetics experiments. 
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Hexokinase I Activity Assay and Kinetics— Hexokinase I activity was determined 
by the glucose 6-phosphate dehydrogenase coupled spectrometric assay (25). Concentrations 
of hexokinase I were determined by Bradford assays using bovine serum albumin as a 
standard (37). Assays were performed in 100 mM Tris-Cl buffer, pH 7.4. Substrate, 
inhibitor and Mg2+ concentrations are provided as footnotes to data tables. Initial rate data 
were analyzed by using a computer program written in MINITAB with an a-value of 2 (38). 
In experiments with AnG6P the kinetic data were fit to a model for linear competitive 
inhibition with respect to ATP, in which one molecule of inhibitor interacts with hexokinase 
I. AnG6P is, in fact, a nonlinear competitive inhibitor with respect to ATP for wild-type 
hexokinase I (29). The nonlinear dependence of inhibition on the G6P concentration, 
however, becomes significant only as concentrations of AnG6P exceed 0.5 mM. As this 
report focuses on the mechanism of inhibition of AnG6P due to its interaction at a single, 
high-affinity binding site, maximum inhibitor concentrations are maintained well below 0.5 
mM. 
Circular dichroism (CD) spectra—CD spectra were measured from 200—260 nm at 
room temperature by using a Jasco J710 CD spectrometer. The concentration of hexokinase 
I used for CD measurements was 0.2 mg/ml in a buffer containing 2 mM Hepes (pH 7.8), 0.2 
mM glucose, and 0.2 mM (3-mercaptoethanol. 
Results 
Rationale for Direct Mutations— Aleshin et al. (22) have proposed an allosteric 
mechanism in which G6P-ligation of the N-terminal half displaces ATP from the active site 
of hexokinase I. The binding of G6P putatively induces a rotation of the N-terminal half 
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about the helix, which connects the two halves of the enzyme (Figure 1). Loop 241—253 of 
the N-terminal half is in contact with the flexible subdomain of the C-terminal half. Hence, 
as the N-terminal half rotates to a new orientation, it induces a conformational change in the 
flexible subdomain of the C-terminal half. Two different orientations of the N-terminal half 
(G6P-bound and Pi-bound), putatively stabilize two conformational states of the flexible 
subdomain of the C-terminal half. 
The conformation of Thr784 may differ significantly in the two states of ligation of the 
N-terminal half. In crystal structures of G6P-ligated hexokinase I (17, 22), Thr784 protrudes 
Backbone carbonyl 747 also hydrogen bonds with the 2'-hydroxy 1 of the adenine nucleotide. 
Mutation of Thr784 to alanine or to leucine will disrupt the hydrogen bond network of the 
ADP-ligated active site, but neither side chain has unacceptable contacts in the G6P-bound 
conformation. 
Leu867 and Thr683 together make numerous nonbonded contacts with the base and 
ribosyl groups of ADP. Depending on which ligand is present, the side chain of Thr863 also 
hydrogen bonds with the 6-phosphoryl group of G6P or the a-phosphoryl group of ADP. 
Leu867 and Thr683 have similar conformations and interactions with each other in both G6P-
into the ribose/base pocket of ATP. In contrast, the side chain of Thr784 hydrogen 
bonds with backbone amide 751 and backbone carbonyl 747 in the ADP-ligated active site 
(Figure 2). and ADP-ligated active sites (22). Leu867, however, may be important only to 
adenine nucleotide interactions with the active site of hexokinase I. Mutations of Leu867 to 
alanine and tyrosine then should test the importance position 867 in the recognition of ATP. 
Product inhibition of the truncated, C-terminal half clearly cannot work through the allosteric 
mechanism, outlined above. Instead, G6P probably binds directly to the active site with its 6-
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Figure 1. Cartoon representation of the proposed allosteric mechanism of G(>P inhibition of 
catalysis in hexokinase I. The conformation of monomelic hexokinase varies in response to 
ligation of its active site (C-terminal half) and its vestigial active site (N-termJnal half). In 
the presence of low concentrations of G6P, the allosteric interface between th_e N- and C-
terminal halves, maintains the flexible subdomain in an ATP-antagonistic state, in which 
Thr784 blocks the base-binding pocket for the nucleotide (A). In the presence of elevated 
concentrations of G6P, the N- and C-terminal halves are decoupled, with G6P bound directly 
to the active site, overlapping the ATP pocket (B). Sufficient levels of P, displace G6P from 
the N-terminal half and allow a rigid-body rotation of that half relative to the » C-terminal half. 
The allosteric interface now stabilizes the ATP-compatible conformation of the flexible 
subdomain, removing Thr784 as a steric obstacle to ATP association (C). ATP binds to the Pi-
stabilized conformer of hexokinase (D). 
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phosphoryl group overlapping the a- and (3-phosphoryl binding sites of ADP (Figure 2). The 
G6P-pocket is well separated from Thr784 and Leu867. Hence, the two proposed mechanisms 
of product inhibition, allosteric for the full-length enzyme and direct for its truncated, C-
terminal half, should respond differently to mutations at positions 784 and 867. From past 
work Thr536, a residue of the C-terminal half, binds directly to the 6-phosphoryl group of 
G6P in crystal structures. Its mutation to alanine abolishes product inhibition of the C-
terminal half, but has little effect on inhibition of the full-length enzyme (32). Conversely, if 
the proposed model for allosteric regulation is valid, mutations of Thr784 and/or Leu867 should 
influence product inhibition of the full-length enzyme, but have little or no effect on 
inhibition of the truncated C-terminal half. 
Expression, Purification, and Secondary Structure Analysis of Wild-type and 
Mutant Enzymes— Wild-type and mutant hexokinases behaved similarly through 
purification protocols. All proteins studied here were at least 95% pure on the basis of SDS-
PAGE (data not shown). The CD spectra of mutant and wild-type hexokinases were 
identical within experimental error (data not shown). 
Functional Properties of Hexokinase I Mutants— Mutations at positions 784 and 
867 reduce kcat by approximately 100-fold relative to the wild-type constructs (Table I). The 
sites of mutation are remote from the glucose pocket, and indeed we observe at most a 
twofold effect on the Km for glucose. 
The data of Fig. 3 are representative of responses by wild-type hexokinases (both full-
length and tuncated) and by alanine mutants of the truncated C-terminal half to a systematic 
variation in the concentrations of ATP and AnG6P at saturating glucose. These data fit a 
model of simple competitive inhibition by AnG6P with respect to ATP: 
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Figure 2. Active site of hexokinase I. {top) ATP- and (bottom) G6P-ligated states as defined 
by crystallographic structures of an engineered monomer of hexokinase I (22). Selected side-
chains, ATP, G6P, and glucose are represented by ball-and-stick models. The ATP molecule 
from the top panel is transformed as a wire frame model to the bottom panel to illustrate 
steric contacts between it, Thr784 and bound G6P. This drawing was done by MOSCRIPT 
(40). 
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l/v = \/Vm[l + KJS(l + I/KÏ)] (Eq. 1) 
In Eq. 1, v is the velocity, Vm is the maximal velocity, Ks is the Michaelis constant for 
ATP, and K\ is the inhibition constant for AnG6P. Goodness-of-fit values for all data sets of 
Table I are 5% or lower. The Km for ATP is generally insensitive to mutations at positions 
784 and 876, increasing at most by threefold. On the other hand, position 784 and 867 
mutations abolish inhibition by AnG6P for the full-length enzyme, but have little effect on 
product inhibition of the truncated, C-terminal half. 
The absence of a major change in the Km of ATP due to mutations at the ATP pocket 
suggests a fundamental error in the identification of the ribose/base binding pocket or 
alternatively the recognition of ATP by a mechanism independent of its base/ribose moiety. 
Assays of wild-type hexokinase I, and its truncated C-terminal half, with nucleoside 
triphosphates other that ATP, namely ITP, GTP, CTP and UTP, reveal catalytic rates 
approximately 30-fold less than that for ATP, and Km values varying from 2 to 8 mM (Table 
II). Perhaps more significantly, AnG6P did not inhibit catalysis of the full-length enzyme 
supported by GTP, UTP or CTP, and exhibited a five-fold increase in IC50 for AnG6P in 
catalysis supported by ITP. In contrast, AnG6P potently inhibited the truncated, C-terminal 
half of hexokinase I, regardless of the nucleoside triphosphate used in support catalysis. 
Discussion 
Several lines of evidence support the binding of G6P directly to the active site of the 
truncated, C-terminal half of hexokinase I. Crystal structures of the full-length enzyme 
reveal G6P bound to a site that overlaps the ATP pocket at the C-terminal half (22). The 
kinetic mechanism of G6P inhibition of the truncated, C-terminal half is competitive with 
respect to ATP (25). Directed mutations of residues that interact with G6P abolish product 
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Table I. Kinetic parameters for wild type and mutant forms of hexokinase I 
Enzyme3 Specific activity 
(units/mg protein/ min) 
^cat 
(sec"1)b 
ATP 
(mM)b 
TJ* Ulucose 
-^m 
(HM)C 
AnUbP 
(jjM)b 
Wild-type, fHKe 6Î.2+O.9 102±2 O.44+O.OÎ 41±2 18±2 
Wild-type, cHKe 55+1 45.6±0.9 O.5+O.Î 52±4 25±2 
Thr784—>Ala, fHK 0.81±0.05 Î.35+O.O9 0.90±0.08 110±20 d 
Thr784—>Leu, fHK O.64±O.O7 1.1±0.1 1.14±0.07 28+2 d 
Thr784—>Ala, cHK 1.5+0.1 0.90±0.08 Î.2+O.Î 33±1 40±2 
Leu867—» Ala, fHK 0.55±0.01 O.92+O.O8 0.91±0.05 55±4 d 
Leu867—>Tyr, fHK 0.93+0.02 Î.6O+O.O3 Î.8+O.Î 28±3 d 
Leu867—>Ala, cHK Î.2+O.O4 O.72±O.O2 O.64+O.O5 40±3 74±5 
Table I footnotes. 
afHK is full-length hexokinase I, and cHK is the truncated C-terminal half of hexokinase I, 
residues 455—917 of hexokinase I. 
^Determined from experiments, which systematically vary the concentration of ATP and 
AnG6P. Concentrations of ATP vary from 1/3 to 3 times ATmATP. Concentrations of AnG6P 
are 0, 1,2, 3, and 4 times ATiAnG6P. All glucose concentrations are fixed at 2 mM. Mg2-r 
concentrations are 3 mM above those for ATP. Data are fit to a model for simple 
competitive inhibition (Eq. 1). 
^Determined from experiments, which systematically vary the concentration of glucose. 
Glucose concentrations are 10, 20, 40, 60, 80, 100, 150, 200, and 300 pM. All ATP 
concentrations are fixed at 5 times KmATP. Mg2+ is 3 mM in excess of the concentration of 
ATP. 
dNo detectable inhibition by AnG6P up to 1 mM. 
eTaken from (32). 
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Figure 3. Plots of initial velocity versus ATP at selected concentrations of AnG6P for 
mutants of the truncated, C-terminal half of hexokinase I The mechanism of inhibition by 
AnG6P with respect to ATP for the (top, A) Thr784—>Ala and (bottom, B) Leu767-»Ala 
mutants enzymes is competitive. Details of the experiment are in the text and footnotes to 
Table I. Concentrations of AnG6P used in experiments: •, 0;, 100 jiM; •, 200 |_IM; <>, 
300 NM; •, 400 FIM. 
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inhibition of the truncated, C-terminal half (32). 
Evidence equally compelling also supports a high-affinity association of G6P with the 
N-terminal half of hexokinase I. G6P at low concentrations protects the truncated, N-
terminal half from proteolysis (31). Mutations at the G6P pocket that abolish product 
inhibition of the truncated, C-terminal half of hexokinase I, do not influence product 
inhibition of the full-length enzyme (32). Crystal structures reveal a high-affinity binding 
site for G6P at the N-terminal half of the enzyme (22). 
Results here clearly reveal fundamental differences in the molecular mechanisms of product 
inhibition for full-length and truncated hexokinase I. Mutations of Thr784 or Leu867 to alanine 
have little effect on product inhibition of the truncated, C-terminal half of hexokinase I, but 
abolish AnG6P inhibition of the full-length enzyme. AnG6P inhibits the wild-type C-
terminal half in catalysis supported by GTP, ITP, CTP, and UTP, but is ineffective as an 
inhibitor of the full-length, wild-type enzyme in the presence of the same nucleoside 
triphosphates. Product inhibition of the truncated, C-terminal half is due unambiguously to 
the binding of G6P directly to the active site. In this binding mode, the 6- phosphoryl group 
of AnG6P will compete directly with the polyphoshoryl moiety of any nucleoside 
triphosphate. If AnG6P were to bind to the full-length enzyme in the same fashion, then it 
should inhibit catalysis regardless of the mutations considered here or the choice of 
nucleoside triphosphate. In fact, AnG6P is a potent inhibitor of the full-length, wild-type 
enzyme only with respect to ATP. 
The observations above are consistent with the proposed mechanism of allosteric 
inhibition due to product-ligation of the N-terminal half. In that mechanism, G6P-ligation of 
the N-terminal half of hexokinase I leverages a conformational change involving Thr784, 
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Table IL Kinetic parameters of full-length and truncated hexokinase I with common 
nucleoside triphosphates 
Nucleoside 
Triphosphate 
Specific activity 
(units/mg protein/min) 
kczi 
(sec-1)3 
r- NTP 
-"-m 
(mM)3 
IC50-A11G6P 
(^iM)b 
Full-length enzyme: 
ATP 54±1 91±2 O.53+O.O4 20+1 
ITP 1.8+0.2 3.0±0.2 2.9+O.7 94+4 
GTP 2.1±0.9 4+2 2.9+O.5 C 
UTP 2.25±0.06 3.8+O.Î 5.9+O.4 c 
CTP 1.62+0.03 2.68+O.O6 3.3±0.2 c 
Truncated, C-terminal half: 
ATP 44±1 36.7±0.5 O.47+O.O2 28±1 
ITP 2.2O+O.O5 Î.83+O.O4 1.95±0.09 38±1 
GTP 1.99±0.04 1.66±0.03 4.5±2 Î2.8+O.7 
UTP 1.0±0.1 0.8±0.1 7.8+2 28.4±0.3 
CTP 1.37±0.05 Î.Î4+O.O4 4.6±O.2 6.2+0.9 
Table II footnotes. 
"Determined from a series of assays in which the concentration of glucose was 2 mM and the 
concentrations of the nucleoside triphosphates varied from 1/3 to 3 times KmNTP. 
^Concentration of AnG6P that causes 50% inhibition. NTP concentrations were equal to 
their respective Km values, and the glucose concentration was 2mM. 
®No detectable inhibition by 1 mM AnG6P. 
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which impairs ATP recognition (see Results). The absence of product inhibition in the 
mutant enzymes studied here may arise from the failure of the G6P-ligated, N-terminal half 
to stabilize the G6P-inhibited active site. On the basis of modeling, however, none of the 
mutations should destabilize the G6P-inhibited conformation of the active site. Instead, the 
mutations should destabilize the ATP-ligated active site, and indeed, &cat falls 100-fold. 
Rather than the loss of G6P-inhibtion, the mutant enzymes behave as if they are inhibited 
even in the absence of product. Hence, the insensitivity to AnG6P may be the consequence 
of a stabile, G6P-inhibited conformation of the active site. 
ATP is not well recognized as a substrate by the six mutant enzymes (Â"mATP of 
approximately 1 mM, kcat 1% of wild-type levels). Arguably mutant enzymes here recognize 
ATP about as well as the wild-type enzyme recognizes other nucleoside triphosphates (£mNTP 
of 3—8 mM, &cac 3% of levels sustained by ATP). Changes at positions 784 and 867 seem 
not to perturb the polyphosphoryl pocket of ATP, for as noted above, AnG6P still potently 
inhibits mutants of the truncated C-terminal half. On the other hand, residues 784 and 867 
are in contact with the base/ribose of ATP, and hence mutations there should perturb base 
recognition of ATP by the full-length and truncated hexokinases. The enzymes resulting 
from mutations at positions 784 and 867 probably share a common mode of recognition of 
nucleoside triphosphates, are primarily by way of the polyphosphoryl moiety. 
Why, then, is Arcat reduced 100-fold, but Km for ATP only doubled in response to the 
mutations? Most likely the free energy of interaction between ATP and the active site drives 
the C-terminal half of the enzyme into a conformation that facilitates catalysis. Crystal 
structures of hexokinase I have revealed the C-terminal half either in an opened 
conformation, to which glucose binds weakly (18), or in a closed conformation, which binds 
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glucose and G6P with high affinity (22). As the Km for glucose is low for the mutant and 
wild-type enzymes (Table I), the C-terminal half is probably in a closed conformation during 
the rate-limiting step of catalysis. The closed ATP-conformer for the 784 and 867 mutant 
hexokinases must differ, however, from the closed ATP-conformer of the wild-type enzyme. 
Recently, a glucose/ADP complex of wild-type hexokinase (Aleshin, A. E. and Honzatko, R. 
B., unpublished), in which the polyphosphoryl moiety is productively bound to the active 
site, has revealed a C-terminal half in a slightly more opened conformation than that of the 
glucose/G6P complex. Conceivably, glucose/G6P-ligation of the active site may result in an 
"over-closed" conformation, which is unfavorable for the productive association of ATP. 
Catalysis observed from the position 784 and 867 mutant enzymes may arise from this "over-
closed" conformer, rather than from the slightly more opened conformer, which is 
energetically accessible to the glucose/ATP-complex of the wild-type enzyme. 
If product inhibition of the full-length enzyme is by way of an allosteric mechanism, as the 
results here infer, then G6P cannot bind with high affinity to the C-terminal half of the full-
length enzyme. The mechanism, which prevents the association of G6P with the active site 
of the full-length enzyme, is unclear. Occlusion of G6P pocket by the N-terminal half of the 
enzyme is unlikely mechanism, as discussed elsewhere (39). 
Mutations that abolish G6P-ligation of the N-terminal half (29,32), must then "turn-
on" the G6P-binding pocket of the C-terminal half. The restoration of G6P-binding to the C-
terminal half requires a long-range conformational change in the full-length enzyme. An N-
terminal half, unable to ligate P, or G6P, probably favors an opened conformation. Structural 
elements from the N-terminal half, in contact with the C-terminal half, would move 
significantly in a transition from a closed to opened conformer, and result in a significant 
perturbation to the coupling interface between the N- and C-terminal halves of the full-length 
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Figure 4. Image of a model for hexokinase I with an opened N-terminal half, 
an opened N-terminal half would force significant conformational changes on 
half in order to avoid unacceptable steric interactions. 
Presumably, 
the C-terminal 
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enzyme (Figure 4). In crystal structures of an engineered monomer of hexokinase I, the 
contact interface is decoupled, and G6P at micromolar concentrations binds to both halves of 
the enzyme (22). If a decoupled C-terminal half binds G6P with high affinity, then possibly 
the perturbation caused by the opening of the N-terminal half will restore high-affinity 
binding of G6P to the C-terminal half. Hence, in past work, the elimination of potent product 
inhibition required mutations at G6P binding sites of both the N- and C-terminal halves of 
hexokinase I (32). 
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Abstract 
Hexokinase I governs the rate-limiting step of glycolysis in brain tissue, being 
inhibited by its product, glucose 6-phosphate, and allosterically relieved of product inhibition 
by phosphate. On the basis of small-angle X-ray scattering, the wild-type 
enzyme is a monomer in the presence of glucose and phosphate at protein concentrations up 
to 10 mg/mL, but in the presence of glucose 6-phosphate, is a dimer down to protein 
concentrations as low as 1 mg/mL. A mutant form of hexokinase I, specifically engineered 
by directed mutation to block dimerization, remains monomeric at high protein concentration 
under all conditions of ligation. This nondimerizing mutant exhibits wild-type activity, potent 
inhibition by glucose 6-phosphate, and phosphate reversal of product inhibition. Small-angle 
X-ray scattering data from the mutant hexokinase I in the presence of glucose/phosphate, 
glucose/glucose 6-phosphate, and glucose/ADP/Mg^/AlFs are consistent with a rodlike 
conformation for the monomer similar to that observed in crystal structures of the hexokinase 
I dimer. Hence, any mechanism for allosteric regulation of hexokinase I should maintain a 
global conformation of the polypeptide similar to that observed in crystallographic structures. 
Introduction 
Hexokinase I (ATP: D-hexose 6-phosphotransferase, EC 2.7.1.1) governs the flow of 
glucose into the energy metabolism of brain tissue and red blood cells (1). The type I 
isozyme [one of four isozymes found in mammals (2)] consists of a single polypeptide of 
molecular mass 100 kDa, which shows 50% sequence identity between its N- and C-terminal 
halves (3,4). The sequence identity putatively is a consequence of duplication and fusion of 
a primordial hexokinase gene (5-8). Hexokinase I uses ATP to phosphorylate the 6-hydroxyl 
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group of glucose and is inhibited potently by the product, glucose 6-phosphate (G6P). 
Hexokinase I is distinct from isozymes II-IV in that inorganic phosphate (Pi) at physiological 
levels can relieve inhibition by G6P (9-11). 
At low concentrations (below 10 ug/mL of enzyme) typical for kinetics 
investigations, hexokinase I is putatively a monomer (12). At elevated concentrations (above 
10 mg/mL), hexokinase I aggregates and appears as a dimer in all crystallographic structures 
(13-16). The extent to which dimerization of hexokinase I perturbs the conformation of the 
monomer is unclear. Crystallographic dimers have hinge elements which permit rigid-body 
movements of structural domains within the N- and C-terminal halves. More significantly, 
the long transition helix between the two halves of a monomer has the propensity to bend 
and/or reorient (13, 16). A bent or reoriented transition helix could allow a monomer to adopt 
a radically different conformation in solution, in which the N-terminal half of hexokinase I 
establishes an extensive new interface with the C-terminal half. The new interface would 
involve elements of the active site of the C-terminal half. Hence, in order to develop a correct 
model for allosteric regulation in monomelic hexokinase I, the limits of conformational 
change in the monomer under various states of ligation must be defined with greater 
certainty. 
Unfortunately, experimental methods currently available to probe macromolecular 
conformation have in common a requirement for high protein concentration in solution. In 
the case of hexokinase I, the enzyme concentrations necessary for the growth of crystals, and 
for experiments in NMR and light scattering, creates in solution a mixture of dimers and 
monomers of the wild-type enzyme. Reported below are the properties of a mutant 
hexokinase I, in which residues critical to the stability of the dimer have been changed by 
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directed mutation. On the basis of small-angle X-ray scattering data, the resulting mutant 
exists in solution as a monomer at elevated concentrations of enzyme, either in the presence 
or absence of ligands. Furthermore, this nonaggregating form of hexokinase I has kinetic 
properties nearly identical to those of the wild-type enzyme. Under all conditions of ligation 
explored here, the nonaggregating mutant has a rodlike conformation in solution, which is 
similar to that observed for a single polypeptide chain of the crystalline dimer. Hence, 
allosteric regulation of catalysis in monomeric hexokinase I probably involves an interface 
between the N- and C-terminal halves, similar to ones currently defined by crystal structures. 
Materials and Methods 
Materials—A full-length cDNA of human brain hexokinase, cloned into an expression 
vector pET-1 la (from Novagen) to produce pET-1 la-HKI, was available from a previous 
study (17). The Transformer Site-Directed Mutagenesis Kit is from Clontech Laboratories. 
Inc. T4 polynucleotide kinase, T4 DNA ligase, plasmid pGEM-7Z(+), the Magic Miniprep 
DNA purification system, and restriction enzymes were from Promega. Oligonucleotide 
synthesis and DNA sequencing were done at the Iowa State University Nucleic Acid Facility. 
Escherichia coli strain ZSC13, which does not contain endogenous hexokinase. was a gift 
from the Genetic Stock Center, Yale University. ATP, NADP, streptomycin sulfate. 1.5-
anhydro-D-sorbitol, deoxyribonuclease I (DNAase I), leupeptin, phenylmethanesulfonyl 
fluoride (PMSF), and ampicillin were from Sigma. Glucose 6-phosphate dehydrogenase 
came from Boehringer Mannheim. Isopropyl-l-thio-|3-D-galactopyranoside (IPTG) was from 
BioWorld. Bio-gel hydroxapatite came from Bio-Rad and DEAE-Toyopearl 650M resin was 
from TosoHass. 
Rationale for Mutations—The critical interactions which putatively stabilize 
crystallographic dimers of hexokinase I are at the 1-6 interface (Figure 1). The 1-6 interface 
is preserved in two conformational states of the dimer, which differ significantly from each 
other (13,114). Glu280, Arg283, and Gly284 are at the 1-6 interface in crystallographic dimers 
and yet arse remote from known ligand binding sites of the N-terminal half and from the 
interface between N- and C-terminal halves within a monomer. The mutation of Glu280 and 
Arg283 to# alanine eliminates hydrogen bonds between monomers of crystallographic dimers 
and the mrutation of Gly284 to tyrosine introduces steric hindrance. The main chain angles 
(cp= -113°-, \|/= 2°) and the structural context of Gly284 permit the introduction of a tyrosvl 
side chaim, which would project out from the surface of the protein. 
Coanstruction of Mutant Hexokinase Genes —Mutagenesis was performed according 
to protocols provided with the Transformer Site-Directed Mutagenesis Kit, except that 
alkaline deeaaturation/ethanol precipitation was employed to produce single-strand plasmids 
instead of"heat denaturation. The triple mutation, (Glu280 ->Ala/Arg283 ->Ala/Gly2S4 -VTyr). 
was introcHuced by means of an oligonucleotide of the following sequence: 
5'-CAGACGTTTGACAGGGCAATTGACGCATATTCCCTCAACCCTGG-3' 
where alt*ered codons are in boldface type. The primer used for selection, 5'-
GAGCCrCGCCTCGAGAACGCCAGCAAG-3', converts the unique Nrul site to another 
unique Xfaol site. The mutation was confirmed by sequencing the entire insert by the 
fluorescein^, dideoxy chain termination method (Iowa State University DNA Facility). 
Expression and Purification of Wild-Type and Mutant Hexokinase /--Wild-type and 
mutant forms of hexokinase I were produced by growing pET-11 a-HKI-transformed E. coli 
strain ZSC213 overnight in LB medium plus 40 gg/mL ampicillin. The resulting innoculant 
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Figure 1. Stereo view of the 1-6 interface of the hexokinase I dimer. Two polypeptide chains 
are represented in different line widths. The main-chain elements of residues, which 
contribute nonbonded contacts to the 1-6 interface, are in bold lines with black dots 
representing the positions of mutated residues. Residues 242-250 of the N-terminal half and 
796-813 of the C-terminal half may be important to the allosteric mechanism of hexokinase I. 
Glucose molecules (space filling representation) at the N- and C-terminal halves mark the 
approximate locations of allosteric and active sites, respectively. The image is drawn with 
MOLSCRIPT (34). 
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was added to a 100-fold volume of M9 medium with 100 gg/mL ampicillin. The culture was 
grown in a fermenter (with stirring of 200 rpm and a filtered air flow of 6 L/min) at 37 "C to 
early log phase (Aeoo = 0.4), after which isopropyl-(3-D-thiogalactopyranoside (IPTG) was 
added to a final concentration of 0.4 mM to induce the T7 RNA polymerase gene. The 
culture was grown for an additional 20-24 h at 22 °C. The wild-type and mutant forms of 
hexokinase I were purified by streptomycin sulfate precipitation, DEAE-anion exchange 
column chromatography, hydroxyapatite column chromatography, and DEAE 5PW 
Spherogel TSK-G HPLC chromatography as described elsewhere (13, 14, 18). The final step 
of purification separated the enzyme into two electrophoretically indistinguishable 
components. The leading fraction, which contained 75% of the total activity, was used in 
studies reported here. 
Measurement of Protein Concentration—Concentrations of wild-type and mutant 
hexokinases used in kinetics assays were determined by the method of Bradford (19). using 
bovine serum albumin as a standard. Protein concentrations for small-angle scattering 
experiments were determined spectrophotometrically at a wavelength of 280 nm, using an 
extinction coefficient of 0.52 mL mg"1 cm"1. 
Preparation of 1,5-Anhydroglucitol 6-phosphate—The barium salt of 1,5-
anhydroglucitol 6-phosphate (AnG6P) was prepared as described elsewhere (20). A precisely 
weighed amount of the barium salt of AnG6P was dissolved in distilled water by adding HC1. 
Barium ions were removed by titration with a stoichiometric amount of 1 M NaiSOj 
followed by centrifugation. 
Hexokinase Assay and /Knetics—Hexokinase activity was determined by the 
Glucose-6-phosphate dehydrogenase coupled spectrometric assay as described elsewhere 
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(21). Mutant and wild-type enzymes were dialyzed against 50 mM Hepes, pH 7.5. just prior 
to their use in activity assays. Glucose 6-phosphate dehydrogenase was dialyzed exhaustively 
in order to remove ammonium sulfate. Assays were performed in Hepes/sodium acetate (50 
mM/100 mM, pH 7.8). Care was taken to minimize the introduction of phosphate and/or 
sulfate as contaminants of assay components. Mg2+ was added to each assay to a 
concentration of 2 mM in excess of the ATP concentration. Th.e concentration of hexokinase 
used for activity assays was 1.2-2.0 gg/mL. The concentrations of AnG6P used in the 
determination of K\ and K\\ were 0, 100, 200, 300, and 400 |iM, at ATP concentrations of 4.0. 
2.3, 0.90, 0.60,0.45, and 0.30 mM. Phosphate relief of product inhibtion employed an ATP 
concentration of 0.60 mM, Pj concentrations of 3 and 6 mM, and concentrations for AnG6P 
as above for the determination of K\ and Ktl. Initial rate data were analyzed by using a 
computer program written in MINITAB language with an a value of 2.0 (17). Data 
representing the relation of reciprocal velocity to concentrations of ATP and AnG6P were 
fitted to a kinetic model for nonlinear competitive inhibition: 
1/ v =(1/ Vm)[l + (AVA)(1+1IKt-+ I2/KtKél)] (1) 
In the above, v, Vm, and A represent initial velocity, maaimum velocity, and ATP 
concentration, respectively, and K& Klt and Ka represent dissociation constants for ATP. a 
high affinity binding site for AnG6P, and a low affinity site for AnG6P, respectively. 
Equation 1 and its associated kinetic scheme were presented ire. previous work (18). 
Circular Dichroism Measurements—CD spectra were measured from 200 to 260 nm 
at room temperature from samples of mutant and wild-type hexokinases (protein 
concentrations of 200 ug/mL in 2.0 mM Hepes, pH 7.5, 0.1 mM glucose, and 0.25 mM (3-
mercaptoethanol, with and without 1 mM G6P, using a Jasco J710 CD spectropolarimeter. 
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Modeling of Monomers—Crystal structures of hexokinase I dimers [PDB accession 
codes 1HKB) (14) and 1HKC(13)] are points of departure in modeling plausible 
conformational states of monomeric hexokinase I. The models are used in the calculation of 
scattering intensities (see below). A single polypeptide chain and the entire dimer of the 
Glc/G6P complex [PDB accession code 1HKB (14)] were adopted as models for monomers 
and dimers in solution, respectively. In these models, both the N- and C-terminal halves are 
in a closed conformation (14). Models with open N- and/or C-terminal halves were built by 
superposition of an open N-terminal half (using its small domain) and/or an open C-terminal 
half (using its large domain) onto corresponding domains of a single polypeptide chain from 
the Glc/G6P complex. Models for open N- and C-terminal halves come from a previous 
study (13). 
Other models were developed in order to ascertain the global conformational state of 
the monomer under different conditions of ligation. Small-angle scattering intensities are 
sensitive to conformational changes, which alter the gross structure or anisometry. Hence, 
distinguishable models of the monomer (at the resolution of small-angle scattering data) 
require repositioning of the N-terminal half relative to the C-terminal half so as to 
significantly change the global conformation of the polypeptide chain. The calculated 
scattering intensities are insensitive, however, to the exact details of the conformational 
change. Hence, we arbitrarily let the axis of the transition helix define the principal direction 
of the monomer and the Ca atom of residue 475 (which lies at the C-terminal end of the 
transition helix) be a point of articulation. Fixing the C-terminal half in place, the transition 
helix and its attached N-terminal half can be reoriented by rotations about an axis 
perpendicular to the transition helix. Superposition of the N-terminal half of hexokinase I 
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onto the C-terminal half reveals a different orientation of the first helix of the N-terminal half 
relative to the transition helix. The axes of the transition helix and the first helix of the 
superimposed N-terminal half define a plane. The rotation axis used to generate models here 
is perpendicular to this plane. 
Small-Angle X-ray Scattering—X-ray scattering data were collected on the EMBL. 
x33 camera (22-24) on the storage ring DORIS m of the Deutsches Elektronen Synchrotron 
(DESY) using multiwire proportional chambers with delay line readout (25). At the sample-
detector distance of 3 m and a wavelength X of 0.15 nm, the sampled range of momentum 
transfer was 0.1 <s <2 nm"1 [s = (4il sin 8)/ X, where 28 is the scattering angle]. Scattering 
intensities were measured from either wild-type or the interface mutant hexokinases (protein 
concentrations varying from 0.4 to 16 mg/mL) in a buffer containing Hepes (50 mM. pH 
7.8), dithiothreitol (2 mM), glucose (1 mM) and (3-mercaptoethanol (1 mM) with either (i) 
G6P (1 mM)/sodium acetate (100 mM), (ii) P, (1 mM)/sodium acetate (100 mM). or (iii) 
ADP (10 mM)/NaCl (100 mM)/Mg(N03)2 (20 mM)/NaF (5 mM)/ Al(NOs)3 (0.5 mM). The 
data were normalized to the intensity of the incident beam, and corrected for detector 
response. Scattering due to the buffer was subtracted, and the resulting difference curves 
were scaled to the enzyme concentration. All procedures involve statistical error propagation 
using the program SAPOKO (D.I.S. and M.H.J.K., unpublished material). 
The forward scattering 7(0) and radius of gyration Rs of individual curves were 
evaluated using the Guinier approximation, /exp(j) = /(0)exp(-j2/?g2/3), which is valid for 
(s/?g) <1.3 (26) and also from the entire scattering curve using the indirect transform package 
GNOM (27). The maximum dimensions of the hexokinases were estimated by use of the 
orthogonal expansion program ORTOGNOM (28). The extrapolated forward scattering value 
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1(0) was used to evaluate the molecular mass of the solute after normalization against the 
reference scattering from solutions of bovine serum albumin. 
Scattering curves from models were calculated using the program CRYSOL (29). 
which takes into account the scattering from the solvation shell at the surface of the protein 
model. The model is covered by a hydration layer of thickness 0.3 nm with an adjustable 
density P&, which may differ from that of the bulk solvent Ps. The scattering from a particle in 
solution is 
where Aa(s) is the scattering amplitude from the particle in vacuo, As(s) and Ab(-î) are. 
respectively, the scattering amplitudes from the excluded volume and the hydration layer, 
both with unitary density, 8Pb = Pb - Ps, and the brackets (< >) stand for the average over all 
particle orientations [fl is the solid angle in reciprocal space, s = (s, fi)]. The program uses the 
multipole expansion of the scattering amplitudes to facilitate the spherical average in eq 2. 
For solutions containing only monomers, calculated scattering curves (derived from models 
built as described above) were fit to experimental scattering curves using two free 
parameters, the excluded volume of the particle, and the contrast of the hydration layer oPh. 
For solutions containing mixtures of monomers and dimers, the volume fractions of each 
component was determined by fitting the experimental data with linear combinations of 
calculated scattering curves from monomers and dimers, using the program OLIGOMER 
(D.I.S, unpublished material). 
(Eq. 2) 
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Results 
Protein Purity and Circular Dichroism (CD) Spectra—On the basis of SDS-PAGE. 
wild-type and interface mutant enzymes were at least 95% pure (data not shown). The CD 
spectra of the wild-type enzyme and the interface mutant enzyme coincide. The addition of 
G6P to 1 mM did not influence the CD spectrum of either enzyme (data not shown). 
Kinetic Studies —Kinetics parameters foir wild-type and mutant hexokinases are 
identical to within experimental uncertainty (TaBble 1). The Km for ATP and the K\ for AnG6P 
differ for the wild-type and mutant enzymes by approximately 3 and 4 standard deviations, 
respectively. The reported standard deviations, hnowever, derive from the random distribution 
of data about the model for a specific experiment and do not reflect systematic errors, which 
may arise from variations in stock solutions and different preparations of enzyme. The Km for 
ATP of the wild-type enzyme, for instance, has waried from 0.4 to 1.2 mM with an average 
value of 0.6 mM. Hence, the observed Km for the mutant is indistinguishable from that of the 
average for the wild-type enzyme. The K\ for AniG6P is sensitive to the level of phosphate 
contamination in the ATP stock solution, as well! as the precise determination of ATP 
concentration. The specific activity of wild-type and mutant enzymes under the conditions of 
assay here are 61 ± 7 and 60 ±4 gmol mg"1 min""1, respectively. These values are equal to 
those reported for hexokinase I purified from nantural sources. The wild-type and interface 
mutant enzymes follow the nonlinear competitive mechanism (Eq 1, goodness of fit 5%). the 
two enzymes exhibiting comparable values for Ht and Ktt. The high uncertainty in the K„ 
value is a consequence of the threshold concentration (400 jxM) of AnG6P, which is too low 
for an accurate determination of a low affinity interaction. Enzyme velocities are very low 
and subject to significant error at millimolar concentrations of AnG6P, complicating kinetic 
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Table 1. Kinetic parameters for wild-type and interface-mutant hexokinases1. 
Kinetic Wild-type Interface mutant 
Parameter hexokinase I2 hexokinase I2 
(s"') 100(10) 100(6) 
Km (Glucose) (gM) 61(6) 57(5) 
Km (ATP) (mM) 1.2(0.2) 0.66(0.06) 
Ki (AnG6P) (|iM) 15(2) 23(2) 
Ka (AnG6P) (mM) 1.4(0.4) 3(2) 
Pi relief 3 (%) 72(6) 80(6) 
Table I footnote. 
1 Values in parentheses are standard deviation. 
2 Ki and AT;; were obtained by fitting data (plots of 1/velocity versus 1/[ATP] at 2 mM glucose 
with AnG6P ranging from 0 to 400 fiM) to a model for nonlinear competitive inhibition 
(Eq. 1). 
3 Percent relief of AnG6P inhibition by P; was determined as follows: 100x(A-B)/A. where A 
is the slope from the plot of (relative velocity of hexokinase)"1 versus AnG6P concentration 
(as in Fig. 2) in the absence of Pi and B is the slope from the plot of (relative velocity of 
hexokinase I)"1 versus AnG6P concentration in the presence of 6 mM P,. 
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Figure 2 Models of hexokinase I used in the analysis of small-angle scattering data. In all images, the C-
terminal half is on the bottom, small domains (residues 75-209 and 448-465 of the N-terminal half and residues 
523-657 and 896-913 of the C-terminal half) are yellow, large domains (residues 210-447 of the N-terminal half 
and 658-895 of the C-terminal half) are green, the interdomain helix (residues 448-475) is purple, and ball-and-
stick representations of bound glucose, Glc-6-P and ATP are red, blue, and purple, respectively. The ligand 
binding sites are those observed in crystal structures (13, 14) except for that of ATP which comes from a model 
(14). P; binds to the N-terminal half at the phosphoryl site of G6P. (a) A single polypeptide chain from the 
G 6 P / g l u c o s e  c o m p l e x  ( P D B  a c c e s s i o n  l a b e l  1 H K B ) ,  i n  w h i c h  b o t h  h a l v e s  a r e  i n  a  c l o s e d  c o n f o r m a t i o n  (  1 4 ) .  t b >  
The model corresponding to a rotation angle of -20 (see text for definition of the rotation angle). Note the loss 
of contacts between the N- and C-terminal halves, (c) The model corresponding to a rotation angle of 35 ° . The 
relative orientations of the transition helix (purple) and the corresponding helix (residues 16-27) of the N-
terminal half are the same, (d) The model corresponding to a rotation angle of 80 ° . The N-terminal half is in 
direct contact with G6P-binding site of the C-terminal half, (e) A different orientation of the model in uu to 
facilitate comparison to the model of (f) where both halves are in an open conformation. Images of hexokinase I 
drawn with MOLSCRIPT (34) and RASTERSD (35). 
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assays under conditions, which in principle should allow a more precise determination of Kh. 
Phosphate relieves inhibition by AnG6P for wild-type and interface-mutant hexokinases to 
approximately the same extent. The kinetic parameters for the wild-type enzyme essentially 
are unchanged from those of the previous study (18), except for kcat, which differs slightly 
due to differences in the buffer system used here (Hepes/sodium acetate, pH 7.8) and in the 
previous investigation (Tris, pH 7.4). 
Models Employed in Calculating X-ray Scattering—Crystal structures of hexokinase 
I reveal different relative orientations for the first helix of the N-terminal half and the 
structurally corresponding transition helix, which lies between N- and C-terminal halves. A 
rotation of 35° about the axis defined in the Materials and Methods and Figure 2 brings the 
transition helix into alignment with the first helix of the superimposed N-half and results in a 
monomer with a more compact structure, similar to a bent rod. A rotation of 80 ° allows the 
N-terminal half to come in contact with elements of the active site at the C-terminal half 
(Figure 2). A rotation of 80° creates a new interface, which could transmit the effects of G6P 
binding at the N-terminal half to the active site of the C-terminal half. Further positive 
rotation results in unacceptable steric interactions. Rotations in the opposite direction 
(hereafter defined as rotations through negative angles) initially produce a more extended 
monomer (-20° rotation) with no contacts between the N- and C-terminal halves. Further 
negative rotation leads to bent-rod structures, which are indistinguishable by small-angle 
scattering from those structures generated by positive rotations. Hence, rotations over the 
range -20 to 80 0 sample a full range of global conformations for hexokinase I at the 
resolution of small-angle scattering data. 
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Table 2: Experimentally Determined Radii of Gyration, Molecular Masses, and Maximum 
Intramolecular Distances Calculated from GNOM for Wild-Type and Interface-Mutant 
Hexokinases3 
Sample2 concn (mg/mL) radius of gyration (nm) Mr3 (kDa) Dmax (nm) 
WT, Glc/Pi 14.4 4.70(0.02) 120 15 
7.2 4.53(0.06) 108 16 
3.6 4.22(0.09) 95 15 
WT, Glc/G6P 14.6 4.57(0.04) 250 15 
7.3 4.38(0.06) 240 14 
3.6 4.61(0.09) 255 15 
0.9 4.53(0.15) 265 15 
mutant, .Glc/Pi 16.9 4.18(0.04) 92 15 
8.4 4.65(0.07) 95 15 
4.2 4.34(0.09) 87 15 
1.0 4.43(0.16) 83 15 
mutant, GIc/G6P 14.1 4.32(0.06) 122 15 
7.0 4.37(0.09) 120 15 
3.5 4.35(0.17) 114 15 
1.8 4.37(0.15) 121 15 
0.9 4.34(0.24) 119 15 
0.4 4.23(0.37) 108 14 
mutant, GIc/ADP 12.9 4.04(0.06) 102 14 
6.5 4.14(0.07) 112 14 
3.2 4.41(0.12) 130 15 
0.8 4.12(0.23) 121 15 
Table 2. footnote. 
1 Values in parentheses are standard deviations. 
" Samples contain wild-type (WT) enzyme or interface-mutant enzyme in the presence of 
Glc/Pi, Glc/G6P, or Glc/ADP/Mg2+/A1F3 under conditions provided in the Materials and 
Methods. 
3 Standard deviations of Afr and Dmax are about 15 and 7%, respectively. 
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Small-Angle X-ray Scattering—Molecular weight determinations by small-angle 
scattering rely on an accurate determination of hexokinase I concentration. The direct 
determination of hexokinase I concentration, however, has a 10% uncertainty. This coupled 
with systematic errors in the acquisition of scattering data for each of the concentration series 
of Table 2 translates into a 15% uncertainty in the determination of molecular weight. The 
variations in molecular weight, reported in Table 2, reflect the anticipated level of 
uncertainty. 
Invariants of the scattering curves [the radius of gyration (R g )  and the apparent 
molecular weight of the macromolecule] are consistent with a mixture of monomers and 
dimers for the wild-type enzyme (Table 2, Figure 3). In contrast, solutions of the interface-
mutant enzyme yielded molecular weights and Rg values comparable to those of a monomer 
for all concentrations and buffers. Quantitative estimates of the composition of the 
hexokinase mixtures were obtained using OLIGOMER (see Materials and Methods). In the 
presence of fixed concentrations of G6P or Pi, the volume fraction of dimers increases with 
the concentration of the wild-type enzyme (Table 3). Pj stabilizes the wild-type monomer 
relative to the dimer, whereas G6P stabilizes the dimer relative to the monomer. A significant 
s portion of the wild-type enzyme is dimeric in the presence of G6P, even at the lowest 
enzyme concentration (0.9 mg/mL). The scattering curves from the interface-mutant enzyme 
in all solutions were superimposable (Figure 4), the invariants of each curve being indicative 
of monomeric hexokinase I. Hence, data for the interface-mutant enzyme can be compared 
directly to calculated scattering curves based on various models for the hexokinase I 
monomer. The models and scattering curves were generated as described in the Materials and 
Methods. To test whether the extended conformation of the monomer, observed in the 
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Figure 3. Small-angle X-ray scattering from the wild-type enzyme in Glc/G6P. Curves 1 -4 
correspond to 14.6, 7.3, 3.6, and 0.9 mg/mL enzyme, respectively. Observed data are 
represented by circles. Calculated curves (solid lines) are based on a subunit of the Glc/G6P 
crystalline complex (rotation, 0° ; N- and C-terminal halves closed). 
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Table 3: Volume Fractions Expressed as Percent Monomers and Dimers of Hexolcinase I 
Present in the Solution on the Basis of Small Angle Scattering 1 
Sample2 concn (mg/mL) X3 <Mr>
4 (kDa) <Rg>5 (nm) Monomer
6 
(%) 
Dnmer6 
(%) 
WT, Glc/G6P 14.6 0.670 196 4.41 3.7(1.0) 96.3(0.8) 
7.3 0.464 192 4.41 8.0(1.6) 92.0(1.2) 
3.6 0.451 182 4.39 17.9(2.6) 82.1(1.9) 
0.9 0.283 179 4.39 20.5(7.8) 79.5(5.5) 
WT, Glc/Pi 14.4 1.011 124 4.26 76.2(0.8) 23.8(0.5) 
7.2 0.666 111 4.21 89.4(1.1) 10.6(0.8) 
3.6 0.618 99.9 4.16 100.1(2.0) -0». 1(1.3) 
1.8 0.537 98.7 4.16 101.3(2.5) -1 .3(1.6) 
1.0 0.665 105 4.19 95.4(4.0) 4.'6(2.6) 
mutant, Glc/G6P 14.1 0.522 105 4.19 95.1(1.1) 4/9(0.8) 
7.0 0.369 105 4.19 94.7(1.8) 5.3(1.3) 
3.5 0.527 96 4.14 103.6(2.5) -3-.6(1.7) 
1.8 0.364 104 4.18 96.0(2.9) 4.-0(2.0) 
0.9 0.346 103 4.18 97.2(4.3) 2. 8(3.0) 
0.4 0.251 104 4.18 96.4(11.7) 3.6(8.0) 
mutant, Glc/ADP 12.9 0.694 102 4.17 98.3(1.2) 1.7(0.9) 
6.5 0.449 102 4.17 97.6(1.9) 2.-4(1.4) 
3.2 0.370 106 4.19 93.9(3.3) 6. 1(2.3) 
0.8 0.398 79.9 4.03 120.1(6.4) -2:0.1(4.5) 
Table 3 footnotes. 
1 Values in parentheses are standard deviations. 2 Samples contain wild-type (WT) enzyme or 
interface-mutant enzyme in the presence of Glc/Pi, Glc/G6P, or Glc/ADP/Mg2+/A1F^ under 
conditions provided in the Materials and Methods. 3 Goodness of fit expressed as X2 = (/V -
l)"'Zy[(/(j)) -IexpCs/OM-y/)], where N is the number of data points, I(sj) the calculated cinrve. and 
lexpisj) and a(sj) are the experimental data and their standard deviations, respectively. 4 <Mr> 
is the volume-fraction, weighted average of the monomer Mr (100 kDa) and the dimer Mv 
(200 kDa). 5<Rg> is the volume-fraction, z-average of the radii of gyration of the hydlrated 
monomer (4.16 nm) and dimer (4.42). 6 Volume fractions evaluated by OLIGOMER, (see 
Materials and Methods). The program does not restrict the fractions to be within the range 
0.0-1.0, hence negative values are possible. 
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Figure 4. Agreement in calculated scattering curves and observed scattering data. Scattering 
data are from the interface mutant enzyme in Glc/P, (1), in /Glc/ADP/Mg2+/AlFjs (2). and in 
Glc/G6P (3), and the wild-type enzyme in Glc/P,. (4). Each curve is offset along the vertical 
axis in order to facilitate comparisons between observed data (open circles) and the 
calculated scattering (solid lines) from a subunit of the Glc/G6P crystalline complex 
(rotation, 0 ° ; N- and C-terminal halves closed). 
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Table 4: Goodness-of-Fit between Experimental and Calculated Scattering Curves for the 
Interface Mutant of Hexokinase I1 
model for calculated data goodness-of-fit for interface mutant in 
rotation (deg) C-terminal N-terminal Glc/Pj GIc/G6P Glc/ADP/Mg2+/A1F3 
0 open closed 0.785 0.682 0.565 
0 closed open 0.882 0.740 0.671 
0 open open 0.893 0.780 0.669 
0 closed closed 0.730 0.643 0.536 
35 closed closed 2.11 1.28 1.47 
80 closed closed 3.63 2.01 2.45 
-20 closed closed 0.641 0.462 0.557 
Table 4 footnote. 
1 Calculated curves are determined from the models of Figure 2, using the program CRYSOL 
(29). The last four entries of Table 4 correspond to models of Figure 2, panels f, a. b. c. and 
d, respectively. Models for the first two entries of Table 4 are not illustrated here. 
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Figure 5. Calculated and observed scattering curves from the interface mutant enzyme in 
Glc/Pi. Observed data are represented by circles. Calculated scattering curves are for the isl­
and C-halves closed with a rotation of 0 ° (solid line), 35 ° (short dash), and 80° (long 
dash). 
crystallographic dimers, is a consequence of dimerization, models of Figure 2b and Figure 2c 
were generated using rotation angles of 35 and 80 °, respectively. These more compact 
models, however, gave cattering curves which fit the observed data poorly (Figure 5. Table 
4). Calculated scattering curves from extended models, such as those of Figure 2a and 2b. 
where the rotation angle is either 0 or -20 °, provided excellent fits to the observed data 
(Figure 5, Table 4). The quality of the fit was insensitive to models based on an extended 
monomer with open and/or closed domains (Figure 2, panels e and f). Models, which fit the 
observed data well, have in common a rodlike conformation. This rodlike conformation 
exists in the presence of ligand combinations (Glc/Pi, Glc/G6P, or Glc/ADP/Mg2+/AI F_0. 
which should sample all of the anticipated conformational states of hexokinase I. 
The radius of gyration computed from the atomic model of the monomer is 4.1 nm. 
whereas the experimental values are systematically higher (about 4.2 nm). The increase is 
due to a higher solvent density in the hydration shell (using CRYSOL, contrasts in the 
hydration layer SPb between 14 e/nm3 and 38 e/nm3 for all the fits). These contrasts 
correspond to bound water of about 1.1 g/cm3 and to a protein hydration of about 0.23 g of 
HiO/g of dry protein, in agreement with results obtained previously for other proteins in 
solution (30). 
Discussion 
Small-angle scattering data are consistent with appreciable dimer formation for wild-
type hexokinase I in the presence of 1 mM G6P and 2 mM glucose, whereas in the presence 
of 1 mM Pi and 2 mM glucose, the enzyme is primarily monomeric. The results are in 
agreement with analytical ultracentrifugation studies of hexokinase I from bovine brain, 
which indicate enzyme monomers at total protein concentrations of up to 7 mg/mL and a 
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dimer in the presence of G6P at total enzyme concentrations of 1-1.8 mg/mL (31). Either Pj 
at 10 mM or ATP at 5 mM antagonize dimerization induced by G6P. Easterby (32) reported 
approximately 9% dimer in the absence of G6P at total enzyme concentrations of 2.5 mg/mL 
of hexokinase I from heart. Dimerization is favored by the reduction of ionic strength and 
pH. Sedimentation coefficients increase for hexokinase I from rat brain in the presence of 
G6P at low protein concentration (12). P. reverses the observed increase in sedimentation 
coefficient. The antagonistic effects of G6P and P, putatively demonstrate two 
conformational states for the monomer, but the same study reported monotonie increases in 
sedimentation coefficients with increases in total enzyme concentration, a phenomenon not 
easily reconciled with the existence of a single state of aggregation for the enzyme. Indeed, 
the sucrose gradient used in the latter study could profoundly stabilize the hexokinase dimer. 
Polyethylene glycol, for instance, induces crystallization of hexokinase dimers; the effect of 
polyethylene glycol on the bulk properties of an aqueous solution is not unlike that of a high 
concentration of sucrose. 
In contrast to the wild-type enzyme, the interface mutant remains a monomer at all 
protein concentrations in the presence of all ligand combinations (Table 3). Furthermore, the 
mutant enzyme retains a rodlike conformation in solution consistent with Figure 2, panels a. 
b, e, and f. Small-angle scattering data were insensitive to conformational differences 
between G6P- and Pi-bound states of the mutant, with either state explained equally well by 
models with opened or closed domains (Table 4). No significant change occurs in the radius 
of gyration of the mutant enzyme in response to antagonistic ligands. Observed changes in 
sedimentation coefficient for the wild-type enzyme in sucrose density gradients then are not a 
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likely consequence of conformational differences in monomers, but rather may be due to 
ligand-induced change in the state of aggregation of the wild-type enzyme. 
Small-angle scattering data reported here place distinct limits on the conformational 
changes in monomeric hexokinase I in response to ligand association. Whether it be inhibited 
by the product, relieved of that inhibition by phosphate, or complexed with putative 
transition-state analogues (Glc/ADP/Mg2+/A1F3), the monomer retains a rodlike 
conformation similar to that observed for a single polypeptide chain of crystallographic 
dimers. The interface between the N- and C-terminal halves observed in crystal structures 
involves loop 242-250 of the N-terminal half and residues 796-813 of the C-terminal half 
(Figure 1). The mutation of ArgSOl, involved in a salt link between the N- and C-terminal 
halves of the crystalline dimer, reduces phosphate relief of product inhibition ( 18). a finding 
which also implicates the interface above in the allosteric mechanism. Hence, existing crystal 
structures of hexokinase dimers provide a reasonable approximation of the conformation of 
hexokinase monomers in solution. 
Conformational changes associated with the allosteric mechanism of hexokinase I 
must maintain an extended, rodlike structure. Four kinds of conformational change are 
possible: (i) rotating the transition helix, as done in the modeling here; (ii) bending the 
transition helix at its approximate midpoint; (iii) translating the N- and C-terminal halves in 
opposite directions along the axis of the transition helix; (iv) twisting the N- and C-terminal 
halves in opposite directions about the axis of the transition helix. Types i-iii above require 
rotations, bending, and/or displacements of a magnitude that retains an extended molecule 
with an overall length of 15 nm, whereas any twist (type iv conformational change) would 
not alter overall length. Conformational changes within either the N- or C-terminal half (such 
84 
as domain movements between open and closed conformera) are probably of great 
importance to function, but do not cause a detectable change in the length and/or shape of 
hexokinase I. So far, crystallographic structures of dimers have revealed only a tendency for 
the transition helix to bend modestly at its mid-section (13). 
Small-angle scattering data are inconsistent with any model, whereby the N-terminal 
half occludes the G6P pocket of the C-terminal half of the monomer (4). For the N-terminal 
half to block the G6P pocket of the C-terminal half, the monomer must assume a bent 
conformation (rotation angle of 80 °), which is not observed. Yet, in equilibrium binding 
experiments, only one G6P molecule binds to hexokinase I, whereas in crystallographic 
dimers two molecules of G6P bind to each polypeptide chain (one each at the N- and C-
terminal halves). Hence, some mechanism in the monomer other than occlusion must make 
the binding of G6P to the N- and C-terminal halves mutually exclusive. The data here are 
consistent with a model in which interactions between the N- and C-terminal halves statically 
perturb one of the G6P pockets or a model in which the G6P pockets in the N- and C-
terminal halves are coupled by a mechanism of negative cooperativity. Crystal structures of 
the interface mutant under different states of ligation, could provide more insight regarding 
interactions between ligand binding pockets of the N- and C-terminal halves. To this end 
crystals are now available for the interface mutant enzyme in its complex with G6P. which 
diffract to 1.9 Â resolution. 
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CHAPTER V. CRYSTAL STRUCTURES OF MUTANT HEXOKINASE I 
REVEAL MULTIPLE ADP BINDING SITES AND 
CONFORMATIONAL CHANGES RELAYANT TO ALLOSTERIC 
REGULATION 
Alexander E. Aleshin1, Christina Kirby1, Xiaofeng Liu1, Gleb P. Bourenkov2, Hans D. 
Bartunik2, Herbert J. Fromm1, Richard B. Honzatko1* 
Abstract 
Hexokinase I, the pacemaker of glycolysis in brain tissue, is composed of two structurally 
similar halves connected by an a-helix. The enzyme dimerizes at elevated protein 
concentrations in solution and in crystal structures; however, almost all published data reflect 
the properties of a hexokinase I monomer in solution. Crystal structures of mutant forms of 
recombinant human hexokinase I, presented here, reveal the enzyme monomer for the first 
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time. The mutant hexokinases bind both glucose 6-phosphate and glucose with high affinity 
to their N and C-terminal halves, and ADP, also with high affinity, to a site near the N 
terminus of the polypeptide chain. Exposure of the monomer crystals to ADP in the complete 
absence of glucose 6-phosphate reveals a second binding site for adenine nucleotides at the 
putative active site (C-half), with conformational changes extending 15 Â to the contact 
interface between the N and C-halves. The structures reveal distinct conformational states for 
the C-half and a rigid-body rotation of the N-half, as possible elements of a structure-based 
mechanism for allosteric regulation of catalysis. 
Introduction 
Hexokinase catalyzes the first step of glycolysis, the phosphorylation of glucose by 
ATP to produce glucose 6-phosphate (G6P). In brain tissue and the red blood cell, hexokinase 
regulates glucose metabolism (Lowry & Passonneau, 1964). The enzyme from brain (called 
the type-I isozyme) binds to the surface of mitochondria (Polakis & Wilson, 1985; Xie & 
Wilson, 1988; Wicker et al., 1993; Beutner et al., 1996, 1997, 1998). Here, it interacts 
putatively with permeation pores, composed of porin (a channel protein that spans the outer 
membrane of the mitochondrion) and adenylate translocase (a channel protein that spans the 
inner membrane). The stacked assembly of translocase, porin and hexokinase permits the 
direct exchange of adenine nucleotides between the mitochondrial matrix and the hexokinase 
active site (de Cerqueira Cesar & Wilson, 1998). The kinetic properties of hexokinase I, 
bound to mitochondria and free in solution, are qualitatively similar (Rose & Warms, 1967; 
Purich & Fromm, 1971; de Cerqueira Cesar & Wilson, 1998). 
Hexokinase isozymes I-III have a molecular mass of approximately 100 kDa (Katzen 
& Schimke, 1965), and consist of two halves, each of which resembles yeast hexokinase in 
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sequence and structure (Schwab & Wilson, 1989; Wilson, 1995). Isozyme IV (glucokinase) 
has a molecular mass of 50 kDa, and is similar in sequence and structure to both halves of 
isozymes I-HI. The sequence similarity between the N and C-terminal halves putatively stems 
from the duplication and fusion of a primordial hexokinase gene (Easterby & O'Brien, 1973; 
Holroyde & Trayer, 1976; Ureta, 1982; Manning & Wilson, 1984). 
Although isozymes I-III share the same structural organization, they differ 
significantly in functional properties. Both halves of hexokinase II support catalysis, whereas 
the N-terminal halves of hexokinases I and III are inactive (White & Wilson, 1989; Arora et 
al., 1993). G6P potently inhibits isozymes I-HI, but only for hexokinase I does 
orthophosphate (P,-) relieve product inhibition (Ureta, 1975; Ellison et al., 1975; Fromm, 
1981). In contrast to isozymes I-III, glucokinase (like hexokinase from yeast) is insensitive to 
G6P. 
In crystal structures, G6P binds to both halves of hexokinase I (Aleshin etal., 1998a, 
b; Mulichak et al., 1998). Indeed, G6P binds with high affinity to the truncated N-terminal 
half of hexokinase I (White & Wilson, 1989) and potently inhibits the truncated C-terminal 
half (White & Wilson, 1989; Magnani et al., 1992; Zeng & Fromm, 1995). Single mutations, 
which eliminate G6P-binding to either the N or C-terminal half, have little or no influence on 
G6P inhibition (Zeng et al., 1996; Fang et al., 1998; Sebastian et al., 1999; Liu et al., 1999). 
If mutations at both G6P binding sites are combined, then product inhibition is abolished (Liu 
et al., 1999). Evidently, the binding of G6P to either theN-half (allosteric inhibition) or the C-
half (direct inhibition) of the enzyme inhibits catalysis. Data from equilibrium binding and 
kinetics experiments, however, support only one high-affinity binding site for G6P to wild-
type hexokinase I (Chou & Wilson, 1974; Ellison et al., 1975; Mehta et al., 1988), suggesting 
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the dominance of one inhibitory mechanism or the possibility of anti-cooperative binding of 
G6P to the N and C-termdnal halves (Liu et al., 1999). 
The mechanism of Pj-relief of product inhibition presents yet another paradox. On the 
basis of crystal structures (Aleshin et al., 1998b) and directed mutations (Fang et al., 1998), P, 
associates with high affinity to the N-terminal half at the binding site for the 6-phosphoryl 
group of G6P. Hence, P; «can displace G6P from the N-terminal half. P, and G6P-ligatedN-
terminal halves, however, have nearly identical conformations (Aleshin et al., 1998b). How, 
then can the C-terminal tualf respond differently to a regulatory domain that has the same 
global conformation in its inhibited and inhibition-relieved states? 
At enzyme concentrations typical for kinetics investigations, hexokinase I is a 
monomer (Wilson, 1995;. Aleshin et al., 1999), but at enzyme concentrations used for 
crystallizations hexokinase I is a dimer (Aleshin et al., 1998a, b, c; Mulichak et al., 1998). As 
the contact surface of the putative allosteric interface is small relative to that between subunits 
in the dimer, the dimer m_ay be of limited value in understanding the allosteric mechanism. In 
an effort to address this p-otential shortcoming, we present crystal structures of an engineered 
monomer of hexokinase I, which for the first time reveal an ADP-ligated active site of 
hexokinase and an unexpected binding site for ADP at the N-terminal half. The ADP-ligated 
active site suggests a Mg^-ATP complex of hexokinase, which is in agreement with 
proposed metal-ATP complexes of related enzymes and for the hydrated Mg2+-ATP complex 
of yeast hexokinase derived from solution studies. The ADP-binding site at the N-half is 
proximal to structural elements required for membrane association of hexokinase, reflecting a 
possible role for the N-hallf in the exchange of adenine nucleotides with the mitochondrial 
matrix. ADP and G6P-ligated monomers of hexokinase I reveal different conformational 
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states for the C-terminal half, one of which permits the association of ATP and the other 
antagonizes ATP binding. Rigid-body movements of the N-terminal half in response to the 
binding of P; and G6P, may differentially stabilize the two conformational states of the C-half. 
Results and Discussion 
General properties of engineered hexokinase monomers—Kinetic parameters for the 
engineered monomer of hexokinase I (the triple mutant, Glu280—» Ala, Arg283—>AIa, 
Gly284—>Tyr), are comparable to those of the recombinant, wild-type enzyme (Table 1). The 
triple mutant retains sensitivity to G6P and P;, which clearly demonstrates a functional 
allosteric system. Small-angle X-ray scattering experiments reveal no dimerization of the 
triple mutant up to concentrations of 16 mg/ml in the presence or absence of ligands (Aleshin 
et al., 1999). Consistent with data from X-ray scattering is the growth of a new crystal form 
(space group P2i2i2, a=145.66 Â, 6=145.80 Â, and c=58.13 Â), which has but one 
polypeptide chain in the asymmetric unit and no intermolecular contact characteristic of those 
in the hexokinase dimer. Indeed, intermolecular contacts in crystals of the triple mutant differ 
completely from those of previous crystal forms ofhexokinase I (Aleshin et al., 1998 a, b, c; 
Mulichak et al., 1998). In spite of the differences in lattice contacts, the triple mutant retains 
the same rod-like conformation of the hexokinase I subunit observed in crystals of the dimer 
(Figure 1), consistent with the findings of small-angle X-ray scattering (Aleshin et al., 1999). 
The N and C-terminal halves of the monomer have one molecule each of bound G6P and Glc. 
Each half is in a closed conformation, similar to the closed conformation of yeast hexokinase 
(Bennett & Steitz, 1980). The two structural domains (small and large), which exist in each 
half ofhexokinase I, form a compact structure due to a 17° rotation of the small domain 
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Table 1. Kinetic Parameters for Wild-Type and Mutant Hexokinases 
enzyme kcat KmATP KmGlc K? Pi-relief6 (%) 
WT1 601 ±5 O.44+O.O7 4Î+Î.9 18.2+2.2 72±6 
Triple2 72±4 0.66+0.07 29.4+3.9 2Î.2+Î.8 80±6 
Quadruple3 11±1 1.58±0.05 44.9+3.5 11.3+0.37 85±6 
Thr536—> Ala-mini4 44±5 0.37+0.03 56.8+2.9 N.D.7 N.D.7 
Table I footnotes. 
1 Wild-type hexokinase I. 
^Triple (Glu280—>Ala, Arg283—>Ala, Gly284—>Tyr) mutant of hehokinase I. 
^Quadruple (Glu280—> Ala, Arg283->Ala, Gly284—>Tyr, Thr536—> Ala) mutant of hehokinase I. 
4 Thr536—» Ala mutant of truncated C-half (residues 455-917) of hexokinase I. was 
obtained from plots of 1/velocity versus 1/[ATP] at 2mM glucose with AnG6P ranging from 
0 to 400 nM. 
^Percent relief of AnG6P inhibition by Pi was determined as follows: 100 x (A — B)/A, 
where A is the slope from the plot of (relative velocity of hexokinase)"1 verses AnG6P 
concentration in the absence of Pi and B is the slope from the plot of (relative velocity of 
hexokinase)"1 versus AnG6P concentration in the presence of 6 mM P;. 
7Not detectable. 
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relative to the large domain (Aleshin et al., 1998b). The open conformation has been observed 
in hexokinase I for only the C-terminal half, in a crystalline dimer grown from a solution of 
Glc and P,- (Aleshin et al., 1998b). ADP is required for the growth of crystals of the triple 
mutant, and indeed one molecule of ADP binds to the N-terminal half at a site remote from 
that of G6P and Glc binding (Figure 1). 
The quadruple mutant (Glu280-»Ala, Arg283-»Ala, Gly284—»Tyr, and Thr5j6—»Ala), employed 
in ligand soaks of ADP, combined the non-dimerizing properties of the triple mutant along 
with an active site still competent with respect to catalysis, but insensitive to direct inhibition 
by G6P (Table 1). Indeed, crystals of the quadruple mutant are isomorphous to those of the 
triple mutant, but require a 500-fold increase in G6P concentration in order to grow. (Crystals 
of either the triple or quadruple mutants have appeared only in the presence of Glc, ADP and 
G6P). Hence, in the preparation of ADP-quadruple mutant complexes, G6P is removed from 
crystals by repeated exchange with ADP solutions (see Experimental). Ligand exchange 
reduces the resolution of X-ray diffraction from 2.0 to 2.8 Â (Table 2), suggesting the onset of 
conformational changes in the ADP-quadruple mutant, which disrupt crystalline molecule of 
ADP bound to the N-terminal half at the site noted above in the triple mutant (Figure 1 ). 
Statistics from data collection and refinement for each of the structures are presented in Table 
2. On the basis of PROCHECK (Laskowski et al., 1993), all structural parameters are 
equivalent to or better than those from structures of comparable resolution. Only two out of 
898 residues fall into generously allowed regions of the Ramachandran plot. Estimates of the 
overall root-mean-square error in atom positions (Murshudov & Dodson, 1997) are 0.16 Â 
for the G6P/Glc complex and 0.45 Â for the ADP/GIc complex. 
ADP-ligated active site—In the ADP/GIc complex, the base moiety of ADP is located 
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Figure 1. Overview of (a) the ADP/Glc-monomer complex and (b) the G6P/Glc-monomer 
complex ofhexokinase I The large and small domains of the N and C-halves are purple and 
yellow, respectively. The flexible subdomain (residues 766-812) is dark purple. The side-
chains of the residues 281, 283, and 284, which were altered by mutation to block 
dimerization, are red. ADP moleecules are cyan, glucose molecules are green, the phosphate 
and G6P molecules are dark blues. This drawing was made with MOLSCRIPT (Kraulis, 
1991) and RASTER]D (Merritt c& Murphy, 1994). 
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Table 2. Statistics from data collection and refinement 
Protein Triple mutant* Triple mutant* Quadruple mutant* Quadruple 
mutant* 
Soaking conditions ADP(ATP), Mg2+, G6P, Glc ADP(pure), Mg2+. ADP(pure), 
Mg2+, Glc, A1F4 Glc, 1.5 hours Glc, 5 hours 
Wavelength (Â) 1.05 1.05 1.00 1.00 
Distance to detector (mm ) 100 110 270 250 
Resolution (Â) 1.9 2.0 2.7 2.8 
No. of reflections collected 454,280 286,697 133,320 65,575 
No. of unique reflections 96,631 83,349 30,082 25,491 
% Completeness 98.3 98.6 86.6 77.5 
R S Emerge 0.055 0.048 0.052 0.064 
% Completeness (last shell) 98.3 82.3 50.1 57.0 
Rmerge5 (last shell) 0.55 0.41 0.18 0.44 
Resolution of refinement (A) 8.0-1.9 00 b 1 to o
 
8.0-2.7 8.0-2.8 
R-factor& 0.211 0.211 0.225 0.260 
Rfree ^ 0.258 0.268 0.283 0.310 
No. atoms in refinement 7,822 7,897 7,501 7,263 
No. waters 682 706 307 102 
Root mean squared deviations (Â): 
Bond distance (sigma ) 0.015 (0.02) 0.016(0.02) 0.011 (0.02) 0.010(0.02) 
Angle 1-3 distance (sigma) 0.033 (0.04) 0.036 (0.04) 0.039 (0.04) 0.039 (0.04) 
Torsion 1-4 distance (sigma) 0.036 (0.05) 0.038 (0.05) 0.043 (0.05) 0.040 (0.05) 
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Table 2. Continued. 
Protein Triple mutant* Triple mutant* Quadruple mutant* Quadruple 
mutant* 
Mean B factors (Â2): 
Protein from refinement 35.3 39.0 33.2 50.6 
From Wilson plot 30.6 33.2 35.0 50.6 
Glucose, N-domain 19.8 25.1 16.1 35.0 
Glucose, C-domain 19.9 23.1 16.2 33.7 
G6P, N-domain (occupancy*) 22.4(1.0) 26.0(1.0) 14.1 (0.35) ¥ 
Pi, N-domain (occupancy*) ¥ ¥ 19.4(0.65) 39.7(1.00) 
G6P, C-domain (occupancy*) 22.7 (0.7) 26.6(1.0) 13.4 (0.35) -(0.00) 
ADP, C-domain (occupancy4) - (0-33) ¥ 67.9 (0.65) 74.1 (1.00) 
ADP, N-domain (occupancy"1) 34.3 (1.0) 39.6 (0.6) 46.1 (1.0) 48.5(1.0) 
Table 2 footnotes. 
*Hexokinase I with mutations Glu280—> Ala, Arg283—» Ala, Gly284—>Tyr. *Hexokinase I with 
mutations Glu280->Ala, Arg283^Ala, Gly284->Tyr, Thr536-)-Ala. sRmerge= ££] |Iij - <Ij>| / 
^Otwinowski et al. (1993), Steller et al., (1997), Collaborative Computational Project, Number 4, 
(1994). & R-factor = S ||F0bs| - (FcaicN / 2 |FobsU f°r all reflections [F0bs| > 0. tR-factor based on 5% 
of the data excluded from refinement. ^Obtained by trial-and-error adjustment during refinement. 
*Not bound. ^Estimated value. 
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order (see below). The ADP-quadruple mutant has one molecule of ADP and Glc bound to a 
closed C-terminal half, one molecule of P, and Glc bound to a closed N-terminal half, and a 
between helicies a.9 (residues 783-791) andal 1' (residues 862-867, Figure 2). The 6-amino 
group and the N-l atom of ADP hydrogen bond with backbone carbonyl group 785 and the 
side-chain of Ser788, respectively (Table 3). The 2'-hydroxyI group hydrogen bonds with 
backbone carbonyl group 747. The side-chain of Thr784 is poorly ordered, but one of its 
staggered conformers could hydrogen bond with the 2'-hydroxyi group as well. The (3-
phosphoryl group of ADP occupies the same site as the 6-phosphoryl group of G6P, hydrogen 
bonding with Thr863 (side-chain and amide backbone), Thr680 (side-chain and amide 
backbone), and Ala536 (amide backbone). The a-phosphoryl group of ADP hydrogen bonds 
to backbone amides 536 and 537, as well as the side-chains of Asn537 and Thr863. The 
binding sites for G6P and ADP overlap, providing a structural basis for a mechanism of direct 
inhibition of catalysis, which must be the dominant mechanism in mutants ofhexokinase I, 
which cannot bind G6P to their N-terminal halves (Liu et al., 1999) (Figure 2). ADP binding 
to the active sites of the quadruple mutant and glycerol kinase (Hurley et al., 1993) are 
similar, except for their (3-phosphoryl groups (Figure 3). The y-phosphoryl group in the 
quadruple mutant points away from the 6-hydroxyl group of Glc, the productive binding of 
that group being blocked by loop 532-539. The conformation of loop 532-539 is identical 
with that observed in the G6P/Glc complexes of the wild-type enzyme. Hence, the mutation 
of Thr536 to alanine does not perturb the loop. The conformation of loop 532-539 in the open 
active site ofhexokinase I (Aleshin et al., 1998b), however, differs significantly from that in 
the closed active site, and would allow productive association of the adenine nucleotide 
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Figure 2. Ligation of the C-terminal half of monomelic hexokinase I. Top, The ADP/Glc-
bound active site with ADP and Glc drawn in green, selected side-chains in orange, elements 
of the small domain in yellow, and segments of the large domain in purple. Dotted red lines 
designate donor-acceptor interactions. The electron density (2F0bs-^caic, blue color) covering 
the ADP molecule is from an omit map, contoured at 1 a. Bottom, The G6P/Glc-bound 
active site. ADP in black, taken from the top illustration, represents the overlap with G6P. 
This drawing was made with MOLSCRIPT (Kraulis, 1991) and RASTERSD (Merrit & 
Murphy, 1994). 
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Figure 3. Comparison of the ADP/GIc monomer complex ofhexokinase (left) to the ADP-
complex of glycerol kinase (right). The large domain ofhexokinase is purple and the small 
domain yellow. Dotted red lines indicate donor-acceptor interactions. The {3-phosphoryl 
group of ADP is not productively bound in the ADP/GIc monomer complex due to the steric 
influence of loop 532-539. In the conformation observed for the open C-half (green), 
however, loop 532-539 allows productive binding of the P and y-phosphoryl groups of ATP 
(black lines) with Mg2+ (black sphere). Comparable interactions involving the ADP molecule 
are observed in a ligated complex of glycerol kinase (Hurley et al., 1993). This drawing was 
made with MOLSCRIPT (Kraulis, 1991) and RASTERSD (Merrit & Murphy, 1994). 
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(Figure 3). Using loop 532-539 from the open active site in the context of the closed C-
terminal half, one can model a productive conformation for the (3 and y-phosphoryl groups of 
Mg2+-ATP (Figure 4). The model for the Mg2+-ATP/Glc complex ofhexokinase I shares 
features of metal-ATP complexes of related enzymes (glycerol kinase, actin and hsp70). 
Thr863 of the ADENOSINE motif (Bork et al., 1992) interacts with the ribosyl and a-
phosphoryl groups of ATP, Asp532 (PHOSPHATE I motif) interacts with Mg2+ through 
coordinated water molecules, and loop 679-681 (PHOSPHATE II motif) has conserved 
interactions with the p and y-phosphoryl groups of ATP. The 6-hydroxyl group of Glc is 3 Â 
from the y -phosphorus atom and oriented for an in-line displacement reaction. The terminal 
oxygen atoms of the y -phosphoryl group interact with Lys621 and/or Ser603, backbone 
amide group 681 and the metal cation. Asp657 hydrogen bonds with the 6-hydroxyl group of 
glucose as a proton acceptor, and is a putative catalytic base. The mutation of Asp657 to 
alanine reduces &catby at least 100-fold (Arora et al., 1991). No functional group of the 
protein is evident as a catalytic acid (protonation of ADP as a leaving group), but two of the 
water molecules coordinated to the Mg2+ could transfer a proton to the y -phosphoryl group of 
ATP. Loop 532-539 in the open conformation does not interact with Mg2+-ATP, but a modest 
(1-2 A) conformational movement toward the P and y-phosphoryl groups of ATP would allow 
hydrogen bond formation with backbone amide groups 534-536 and/or the side-chain of 
Thr536. Mutation of Gly534 to alanine results in a 4000-fold reduction in kcat (Zeng et al., 
1998). The model is consistent as well with independent determinations of metal hydration 
and the stereochemistry of metal-coordinated ATP in hexokinase complexes. Electron 
paramagnetic resonance (EPR) spectra indicate the coordination of four water molecules to 
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Figure 4. Stereo view of the Mg2+-ATP/Glc complex of the active site ofhexokinase I. The 
illustration is based on a model derived from the ADP/GIc monomer complex ofhexokinase 
I. Structural elements in purple and yellow are from the large and small domains, 
respectively, of the C-terminal half ofhexokinase I. Elements in green represent loop 532-
539 in its open conformation. Dotted red lines designate donor-acceptor interactions. Mg2+ 
and its coordinate bonds are black, with four red spheres representing coordinated water 
molecules. The 6-hydroxyl group of Glc is in-line with respect to the y-phosphoryl group of 
ATP, with Asp657 acting as a catalytic base. This drawing was made with MOLSCRIPT 
(Kraulis, 1991) and RASTERSD (Merrit & Murphy, 1994). 
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the cation in complexes of yeast hexokinase, and the absence of direct metal-protein 
coordination (Olsen & Reed, 1993). As Mg2+ in the model occupies the pyranose-binding 
pocket for G6P (see below), ample room is available for a completely hydrated cation. Indeed, 
Asp532 and Arg539 of the small domain may hydrogen bond with the metal-coordinated 
water molecules. Such interactions indirectly link the small to the large domain and should 
stabilize a closed conformation for the C-terminal half (Figure 4). The left-handed isomer of 
chromium-ATP binds to hexokinase 15-fold more tightly than the right-handed isomer 
(Rawlings et al., 1993). Mg2+-ATP (Figure 4) adopts the stereochemistry of the left-handed 
chromium-ATP complex; the right-handed complex will fit into the active site, but the 
distance between the 6-hydroxyl group of Glc and the y-phosphorus atom of ATP is 2-2.5 Â 
(as opposed to 3 À for the left-handed complex). On the basis of the present study, we cannot 
determine which of the two chromium-ATP complexes best represents the productive Mg2-r-
ATP complex. 
G6P-ligated active site— G6P (2.0 Â resolution, average B of 26 Â2) reveals a 
different orientation of the pyranosyl group of G6P (Figure 2), relative to that reported 
originally in the dimer complex (Aleshin et al., 1998a). In the monomer complex, the 
pyranose moiety ofG6P is rotated by 180° about its C5-C6 bond, leaving interactions 
between its critical 2-hydroxyl group a Electron density in the vicinity of bound nd the 
enzyme unchanged, but interchanging protein-ligand interactions involving its 1 and 3-
hydroxyl groups (Table 3). This new conformation for G6P provides an adequate fit of the 
electron density from the 2.8 Â resolution dimer complex. Given the superior order and 
resolution of the G6P/Glc monomer complex in the vicinity of the G6P-binding pocket, the 
conformation for G6P in the dimer structure is probably incorrect. An updated deposition for 
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the G6P/Glc dimer complex reflects the conformation observed here for the G6P/Glc 
monomer complex. 
The C-terminal halves of the G6P/Glc and ADP/GIc complexes are in closed 
conformations. Yet significant conformational differences exist between the C-terminal halves 
of the two structures. Thr784, which is in contact with the ribose and base moieties of ADP, 
projects into the ADP pocket in the G6P/GIc monomer complex (Figure 5). Electron density 
difference maps between the G6P/Glc and ADP/GIc complexes reveal conformational 
changes, which extend over residues 776-812 (Figure 5). Aleshin et al. (1998a) called this 
region the flexible subdomain, because it diverged conformationally from corresponding 
segments in the N-terminal half of hexokinase I and in yeast hexokinase. Indeed, this region is 
sensitive to ligation of the adenine pocket, and has high thermal parameters for main-chain 
atoms. Conformational changes in Thr784 directly perturb residues 774-786, which connect 
helix a8 to helix a9 (Figure 5). The side-chain of Ile781 is in contact with the side-chain of 
Leu807. Hence, the conformational change in Thr784 is relayed through non-bonded contacts 
between Ile781 and Leu807 to segment 792-814. That segment is putatively the C-terminal 
side of the allosteric interface ofhexokinase I (Fang et al., 1998). The most significant 
conformational change in segment 792-812 involves loop 792-798. Here, the electron density 
in omit maps is weak (Figure 6), but reproducible in multiple data sets for the ADP/GIc and 
G6P/Glc monomers. Hence, a conformational difference in the adenine pocket (Thr784) 
results in perturbations throughout the flexible subdomain of the C-terminal half, and reach 
the putative allosteric interface ofhexokinase I. 
Yeast hexokinase (G6P-insensitive), hexokinase from Schistosoma mansoni (G6P-
sensitive, and directly inhibited) and hexokinase I (G6P-sensitive, with direct and allosteric 
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Table 3. Selected Interactions from the G6P/Glc- and ADP/Glc-Monomer Complexes. 
Ligand atom Protein contact Distance (Â) 
G6P (C-half7N-half)a: 
Ol OD2 Asp861/Asp413 2.32/2.52 
0D1 Asp861/Asp413 3.12/3.17 
02 N Ser897/Ser449 2.89/2.98 
0D1 Asp532/Asp84 2.87/2.59 
03 OG Ser897/Ser449 2.77/2.77 
0D2 Asp532/Asp84 2.67/2.69 
0D1 Asp532/Asp84 3.24/3.21 
04 0D1 Asp651/Asp209 2.71/2.65 
6-Phosphoryl OG Thr680/Thr232 2.67/2.65 
N Thr680/Thr232 2.81/2.79 
OG Thr863/Ser415 2.51/2.73 
N Thr863/Ser415 3.09/3.07 
OG Thr536/Ser88 2.52/2.68 
N Thr536/Ser88 2.81/2.80 
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Table 3. Continued. 
Ligand atom Protein contact Distance (Â) 
ADP (N-half)*: 
N6 O Leu31 3.28 
ODl Asn384 3.25 
Nl-Watl2 N Leu31 2.88 
ODl Asn384 3.16 
O Met29 2.76 
02' NH Arg30 3.13 
a-Phosphoryl NH1 Arg425 2.79 
NE Arg426 3.09 
(3-Phosphoryl NH2 Arg425 2.86 
NH2 Arg426 3.24 
OH Tyr732c 2.95 
ADP (C-half)3: 
N1 OG Ser788 2.7 
N6 O Lys785 2.9 
02' O Gly747 3.0 
05' OGl Thr863 2.7 
N Thr863 3.2 
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Table 3. Continued. 
Ligand atom Protein contact Distance (Â) 
a-Phosphoryl OGl Thr680 2.8 
N Thr680 2.6 
N Ala536d 2.7 
(3-Phosphoryl N Asn537 2.9 
N AIa536d 2.9 
ND2 Asn537 3.1 
OGl Thr863 3.3 
Table 3. footnotes. 
^Distances are from the G6P/Glc-monomer complex. 
^Distances are from the ADP/Glc-monomer complex. 
cLattice contact. 
dThr536 in wild type hexokinase I. 
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Figure 5. Conformational differences in the flexible subdomain of the C-terminal half of the 
ADP/GIc- and G6P/Glc-complexes. The Ca trace of the ADP/GIc- (bold lines) and the 
G6P/Glc-complexes diverge in the flexible subdomain (residues 792—814). Two 
conformations of Thr784 are shown explicitly. The contact interface between halves of the 
hexokinase I subunit involve interactions between the flexible subdomain and loop 241—253 
of the N-terminal half. 
inhibition) may exhibit specific steps in the evolution ofhexokinase structure and G6P 
inhibition. In the closed Glc complex of yeast hexokinase (Bennett & Steitz, 1980), a sulfate 
anion binds to the 6-phosphoryl site, but does not induce a conformational change in the 
segment equivalent to loop 532-539 ofhexokinase I. In hexokinase from S. mansoni, the 
sulfate anion at the 6-phosphoryl site induces a conformational change in the corresponding 
loop (Mulichak et al., 1998), similar to that observed for hexokinase I (Aleshin et al., 1998a, 
b). Hence, a pattern is emerging that associates G6P sensitivity in hexokinases with the 
conformational mobility of segments corresponding to loop 532-539 in hexokinase I. The 
residues in yeast hexokinase and S. manosi, corresponding to Thr784, adopt a conformation 
similar to that of the ADP/Glc-complex ofhexokinase I. They do not have the conformation 
observed forThr784 in the G6P/Glc-complex ofhexokinase I, even though the hexokinase 
from S. mansoni is arguably in an inhibited state. Evidently, regions corresponding to the 
flexible subdomain in hexokinase I are inflexible in enzymes from yeast and S. mansoni, both 
of which are 50 kDa proteins with no allosteric regulation. Hence, the flexible subdomain 
observed in hexokinase I may be linked to the evolution of its allosteric mechanism. 
Ligand interactions at the vestigial active site of the N-terminal half— The N-terminal half 
ofhexokinase I binds ligands at a locus corresponding to the active site of hexokinases. We 
refer to this site as the vestigial active site, in order to distinguish it from yet another binding 
site at the N-terminal half for adenine nucleotides (Figure 1). The vestigial active site binds 
either G6P/Glc or P/Glc in dimer (Aleshin et al., 1998a, b, c) and monomer complexes 
(reported here). Regardless of the ligand combination (G6P/Glc or P/Glc) or the state of 
oligomerization ofhexokinase I, the N-terminal halves are always in a closed conformation. 
The 6-phosphoryl group of G6P and P; occupy the same site. Glc and the G6P/P, interactions 
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Figure 6. Electron density and refined models for the flexible subdomain in the ADP/Glc-
and G6P/Glc-complexes ofhexokinase I. Electron density from an omit map (2F0bs-Fcaic), 
contoured at 1er from the G6P/Glc-complex, with models for the G6P/Glc-complex (bold 
black lines) and the ADP/Glc-complex (red lines) superimposed (Jop). Electron density from 
an omit map (2F0bs-Fcaic), contoured at 1er from the ADP/Glc-complex, with models for the 
G6P/Glc-complex (black lines) and the ADP/Glc-complex (bold red lines) superimposed 
(bottom). 
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with the vestigial active site correspond closely to those of Glc and G6P at the C-terminal half 
(Table 3). 
Specific mutants ofhexokinase I, which cannot bind product at the C-terminal half, 
are still potently inhibited by G6P (Liu et al., 1999). The mode of inhibition must be 
allosteric, and for such mutants P; is an antagonist of G6P. The structural basis for P,-G6P 
antagonism is clearly the common binding site for the phosphate moiety. No report in the 
literature, however, has yet to explain how nearly identical, closed N-terminal halves can 
evoke different functional responses from the C-terminal half. The obvious difference in P, 
and G6P is the pyranose moiety. The 2-hydroxyl group of the pyranose moiety is absolutely 
required for potent G6P inhibition (Crane & Sols, 1954). The 2-hydroxyl group of G6P 
interacts with the side-chain of Asp84 and the backbone amide and side-chain ofSer449. 
Evidently, the G6P-Ser449 interaction changes the conformation of the polypeptide backbone 
relative to that of the P/Glc-bound N-terminal half (Figure 7). The localized conformational 
change due to the ligation ofSer449 by G6P could well influence the global conformation of 
hexokinase I. Ser449 lies in the first turn of the helix (transition helix), which connects the N-
terminal half to the C-terminal half. The N-terminal halves of monomer and dimer complexes, 
grown in the presence of G6P, have nearly identical orientations relative to their transition 
helices. The dimer complex co-crystallized with Pi, however, differs significantly in the 
relative orientation of its N-terminal half and transition helix. Superposition of the N-terminal 
halves from the G6P/Glc monomer and the P,-/Glc dimer, using the first half of the transition 
helix, reveals a 6° rotation of the entire N-terminal half about the Ca atom of Ala451 (Figure 
7). The rigid-body rotation of the N-terminal half, will necessarily influence the position of 
loop 241-253, relative to the C-terminal half. Loop 241-253 is the N-terminal side of the 
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putative allosteric interface, interacting through hydrogen bonds and steric contacts with the 
flexible subdomain of the C-terminal half (Aleshin et al., 1998a, b, Fang et al., 1998). 
ADP-association with the N-terminal half—ADP binds to the N-half at a site well removed 
from its vestigial active site (Figure 1). The ADP molecule bound at the N-half is well 
ordered (average thermal parameter of 34 Â2), and even after washing crystals of the G6P/GIc 
monomer extensively in buffers free of ADP, electron density remains at this site. The base 
moiety of ADP is stacked between the side-chains of Phe380 and Arg30 (Figure 8). The 6-
amino group and the endocyclicN-1 atom hydrogen bond with the protein directly or through 
a bridging water molecule (Figure 8, Table 3). Arg30 hydrogen bonds with the 2'-hydroxyl 
group, and His27 either hydrogen bonds with the 3'-hydroxy 1 group or Asp23, depending on 
the orientation of its side-chain. The latter interaction may allow ADP to exert a direct 
influence on the orientation of the N-terminal helix, which is essential for the association of 
hexokinase I with mitochondria (Polakis & Wilson, 1985; Xie & Wilson, 1988; Wicker et al., 
1993; Beutner et al., 1996, 1997, 1998). Arg425 and Arg426 bind to the pyrophosphoryl 
group of ADP. Magnesium cations, although present in the crystallization buffer, are not 
associated with the ADP molecule. An additional hydrogen bond to the p-phosphoryl group 
of ADP comes from a lattice contact (Table 3), which may explain the absolute requirement 
for ADP in the growth of the monomer crystal form. 
The ADP site at the N-terminal half ofhexokinase I is probably functional and not an 
artifact of lattice contacts. 8-Azido-ATP labels rat hexokinase I somewhere within the first 100 
residues (Nemat-Gorgani & Wilson, 1986), suggesting the presence of this ADP binding site 
on hexokinase I in solution. (Note in Figure 8 the proximity of ADP to several residues with 
sequence numbers below 100). An ADP (or related) molecule bound to this site could mediate 
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Figure 7. Conformational differences in P,- and G6P-bound N-halves ofhexokinase I. 
Stereoview of the N-half from the Pi/Glc-dimer complex (bold lines) superimposed on the 
N-half of the G6P/Glc-monomer complex, using the entire N-half as the basis for 
superposition (top). The superposition reveals a significant difference in the conformation of 
Ser449, which is a recognition element for the 2-hydroxyl of G6P. Stereoview of the N-half 
of the Pi/Glc-dimer complex (bold lines) superimposed on the N-half of the G6P/Glc-
monomer complex, using the N-terminal half of the transition helix as the basis for 
superposition. The entire N-half pivots about the N-terminus of the transition helix by a 
rotation of 6°. 
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Figure 8. ADP binding site at the N-terminal half ofhexokinase I. The ball-and-stick model 
represents the ADP molecule. Electron density is from an omit map (2F0bs-Fcaic), contoured 
at 1.4 a from the G6P/Glc-complex. Donor-acceptor interactions are indicated by dotted 
lines. 
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association of hexokinase I with the mitochondrial membrane. Alternatively, the ADP site at 
the N-half could be a way-station in the transport of adenine nucleotides to and from the 
mitochondrial matrix. The direct transport of adenine nucleotides to and from membrane-
bound hexokinase I has been suggested by several investigations (BeltrandelRio & Wilson, 
1992; Laterveer et al., 1995; de Cerqueira Cesar & Wilson, 1998). The ADP-binding site is 
not blocked by dimer formation and, thus, can bind to hexokinase dimers. Hexokinase I 
putatively binds to mitochondria as an oligomer of uncertain composition (Xie & Wilson, 
1990; Beutner ef a/., 1996, 1997, 1998; Aleshin et al., 1998c). 
Allosteric mechanism of hexokinase /— The monomer complexes here reveal distinct 
conformational states for the C-terminal half, one of which is ATP-compatible, whereas the 
other is ATP-antagonistic (Thr784 blocks the base moiety of ATP from its binding site). 
Evidently, the N-terminal half also has two conformational states, differing by a 6° rotation 
about the N-terminal end of the transition helix. These observations suggest an allosteric 
mechanism in which the N-terminal half stabilizes the ATP-compatible C-half in one of its 
two orientations and the ATP-anatagonistic C-half in the other orientation (Figure 9). 
Interactions between the flexible subdomain of the C-terminal half and loop 241-253 
of the N-terminal half putatively define the allosteric interface. These structural elements are 
coupled in dimer crystal structures, but in the monomer complexes here, they do not interact. 
A decoupled monomer is probably the major conformer in solution, whenever G6P 
concentrations are sufficiently high to saturate both binding sites of the enzyme (Figure 9). At 
low concentrations of G6P, however, product binds to the N-half and stabilizes the ATP-
antagonistic state of the flexible subdomain. P, displaces G6P, allowing the N-half to stabilize 
the ATP-compatible state. 
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The model above is consistent with that proposed by White & Wilson (1987, 1990). It 
has the same shortcoming as well. If the G6P-ligated, N-terminal half stabilizes the ATP-
antagonistic state ofhexokinase I, it should also facilitate the direct binding of G6P to the C-
terminal half. Hence, G6P inhibition ofhexokinase I should exhibit a second-order 
dependence on the concentration of product-inhibitor. Although G6P is a non-linear 
competitive inhibitor with respect to ATP, the association of the second molecule of G6P is 
much weaker (by two orders) than the first (Fang et al., 1998). In fact, equilibrium binding 
studies reveal only one high-affinity site on hexokinase I for G6P in the presence of Glc 
(Chou & Wilson, 1974; Ellison et al., 1975; Mehta et al., 1988). Thus, either the two G6P 
pockets are coupled anticooperatively (as suggested by Liu et al., 2000) or the direct binding 
of G6P to the C-terminal half is impaired. The structure-based mechanism proposed here 
cannot be reconciled easily with the anticooperative binding ofG6P. 
White & Wilson (1990) suggest that the G6P-binding pocket of the C-terminal half is 
blocked by the N-terminal half. In all crystal structures ofhexokinase I grown in the presence 
of G6P, however, product is bound to both the N and C-terminal halves. The N-terminal half 
does not directly block the G6P pocket of the C-terminal half. The pyranose pocket for G6P at 
the C-terminal half, however, differs in one respect from the corresponding pocket of the N-
terminal half. In the open, C-terminal half of the Pi/Glc-dimer ofhexokinase I, Asp895 forms 
a salt-link with Arg539 (Aleshin et al., 1998b). The Asp895-Arg539 salt link corresponds to 
residue pair Ser447-Arg91 of the N-terminal half, which clearly cannot form the 
corresponding interaction. The Asp895-Arg539 salt link may perturb the conformation of 
Ser897, which corresponds to Ser449 of the N-terminal half. Hence, a structural element 
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Figure 9. Allosteric states of the hexokinase I monomer. The conformation of monomeric 
hexokinase varies in response to ligation of its active site (C-terminal half) and its vestigial 
active site (N-terminal half). In the presence of low concentrations of G6P, the allosteric 
interface between the N- and C-terminal halves, maintains the flexible subdomain in an ATP-
antagonistic state, in which Thr784 blocks the base-binding pocket for the nucleotide (A). In 
the presence of elevated concentrations of G6P, the N- and C-terminal halves are decoupled, 
with G6P bound directly to the active site, overlapping the ATP pocket (B). Sufficient levels 
of Pi displace G6P from the N-terminal half and allow a rigid-body rotation of that half 
relative to the C-terminal half. The allosteric interface now stabilizes the ATP-compatible 
conformation of the flexible subdomain, removing Thr784 as a steric obstacle to ATP 
association (C). ATP binds to the Pi-stabilized conformer of hexokinase (D). 
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critical for the recognition of the 2-hydroxyl group of G6P may not be available in the open ex­
terminai half. 
The significance of the above salt-link is certainly testable by directed mutation, as is 
the role of Thr784 in mediating product inhibition of catalysis. The mutation of Thr784 to 
alanine abolishes G6P inhibition of hexokinase and the mutation of Asp895 to alanine, alone 
causes a threefold decrease in the inhibition constant (denoted K\\ by Fang et al., 1998) for the 
weak G6P interaction (unpublished results). These results, as yet preliminary, are consistent 
with the structural mechanism presented here. 
Experimental 
Experimental Materials— A full-length cDNA of human brain hexokinase, cloned 
into an expression vector pET-1 la (from Novagen) to produce pET-1 la-HKI, was available 
from previous studies (Fang et al., 1998; Aleshin et al., 1999). The Transformer site-directed 
mutagenesis kit is from Clonetech Laboratories, Inc. Phage T4 polynucleotide kinase and all 
restriction enzymes are from Promega. Bio-gel hydroxyapatite resin is from Bio-Rad. 
Toyopearl DEAE-650 M is from Tosohaas. The Iowa State University Nucleic Acid Facility 
performed oligonucleotide synthesis and DNA sequencing. Escherichia coli strain ZSC13 
(DE3), which does not contain endogenous hexokinase, was a gift from the Genetic Stock 
Center, Yale University. ATP, ADP, NADP, 1,5-anhydro-D-sorbitol, deoxyribonuclease I 
(DNase I), leupeptin, phenylmethylsulfonyl fluoride (PMSF), ampicillin and polyethylene 
glycol 8000 (PEG 8000) are from Sigma. Glucose-6- phosphate dehydrogenase is from 
Boehinger Manheim. Isopropyl-1 -thio-(3 -D-galactopyranoside (IPTG) is from Bio World. 
Directed mutation, expression, purification and kineticsThe triple mutant of hexokinase I 
(Glu280—> Ala, Arg283—> Ala, Gly284-» Tyr) was constructed and kinetically characterized in a 
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previous study (Aleshin et al., 1999). The quadruple mutant was constructed by directed 
mutation of the triple mutant, according to the protocols of the Clontech Transformer site-
directed mutagenesis kit. The mutant plasmid was selected from wild-type plasmids by 
switching a unique Nrul restriction site on the pET-11 vector to another unique Xhol site for 
the single point mutation. The primer for mutation Thr536—> Ala is 
5'-GATCTTGGAGGAGÇAAATTTCCGTG-3 where the modified codon is in bold 
typeface and underlined. The oligonucleotide primers used for the selection of the mutant 
plasmid from the wild-type plasmid are 5'-CAGCCTCGCCTCGAGAACGCCAGCAAG-3\ 
for the conversion from the Nru I site to the Xhol site, and 
5'-CCT CGCGT CGCGAACGCC AGC AAG-3 '. for the conversion from the Xhol site back to 
the Nrul site. Mutations were confirmed by sequencing the entire cDNA insert, coding for 
hexokinase I. E. coli strain ZSC13, transformed with mutant pET-1 la-HKI, was grown in LB 
medium at 37°C to an A600 of 0.8, whereupon the temperature was reduced to 22°C and 
LPTG added to a final concentration of 0.4 mM. At 16 to 24 hours after induction, the cells 
were harvested and then re-suspended in 25 mM KPj (pH 7.5), 2 mM glucose, 1 mM EOT A, 
0.4 mM 2-mercaptoethanol, 1 mM PMSF, and 3000 units of DNase I at a temperature of 
4°C. The cells were broken using a French press and centrifuged, after which the supernatant 
was passed through a DEAE column, using a KP,-buffered (pH 7.5), KC1 gradient from 0 to 
0.5 M. The fractions containing HKI were concentrated and then passed though a 
hydroxyapatite column using a KPi-buffered (pH 7.5), KC1 gradient from 20 mM-500 mM. 
Pooled fractions of mutant hexokinase I were further purified by DEAE-HPLC as described 
(Aleshin et al., 1998a). Hexokinase activity was determined by a coupled spectrometric 
assay, using G6P dehydrogenase (Fromm & Zewe, 1962). 1,5-Anhydroglucitol 6-phosphate 
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(AnG6P) is a surrogate for G6P in kinetic studies of G6P inhibition (the coupling enzyme 
degrades G6P but not AnG6P) and was prepared as described (Ferrari et al., 1959). 
Commercial glucose-6-phosphate dehydrogenase comes as an ammonium sulfate 
precipitate. Sulfate anion, which mimics the effect of Pi in the relief of G6P inhibition (White 
& Wilson, 1989), was removed by dialysis. Hexokinase concentrations were determined by 
Bradford (1976) assays using bovine serum albumin as a standard. Initial rate data were 
analyzed by using a computer program written in MINITAB with an a-value of 2.0 (Siano et 
al., 1975). In experiments with AnG6P, the kinetic data were fit to a model for non-linear 
competitive inhibition with respect to ATP, in which two molecules of inhibitor interact 
sequentially with hexokinase I (Fang et al., 1998). 
Crystal preparation— Crystals of the triple and quadruple mutants were grown by the 
hanging drop method. Two protocols produced the same crystal form. In the first, hexokinase 
I mutants were transferred from a storage buffer (30 mM KP; (pH 7.5), 1 mM Glc, 1 mM (3 -
mercaptoethanol) to a buffer consisting of 25 mM ADP (pH 7.5), 1 mM Glc. Equal volumes 
(2.5 fil) of the protein solution (20 mg/ml of mutant enzyme in the buffer above) and a 
precipitant solution (14-18% (w/v) PEG 8000, 100 mM 2-N-morpholinoethanesulfonic acid 
(Mes), pH 5.8-6.5, 200 mM sodium acetate, 20 mM ADP, 2 mM Al(NC>3)3, 10 mM NaF, 30 
mM magnesium acetate) were mixed. The drops were equilibrated against 0.7 ml of the 
precipitant solution. One crystal (dimensions, 0.15 mmx0.15 mm xO.O5 mm) appeared per 
droplet. Although G6P was not added, the crystalline enzyme had two G6P molecules bound 
with high occupancies. G6P was produced by hexokinase from glucose and an ATP 
contaminant in the ADP. The amount of ATP impurity (0.16%) was determined by a yeast 
hexokinase, G6P dehydrogenase coupled spectrometric assay (Fromm & Zewe, 1962), using 
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excess glucose and NADP. The importance of G6P for the growth of this crystal form 
follows from the high ligand occupancy, and from the failure to grow crystals with purified 
ADP. 
In the second crystallization protocol, the protein was dialyzed against 1 mM Glc, 20 
mM G6P (pH 7.5), and then concentrated to 20 mg/ml. Equal volumes (2.5 gl) of the protein 
solution and a precipitant solution (14-18% PEG 8000, 100 mM Mes (pH 5.8-6.5), 150-250 
mM sodium acetate and 20 mM ADP) were mixed. The high concentration of G6P, used in 
the second protocol, provided larger crystals (0.4 mm><0.3 mm><0.2 mm). Data reported in 
column 1 of Table 2 comes from a crystal grown by the second protocol, but the structure of 
the crystal grown by the first procedure is identical. Prior to crystal soaks, contaminating 
ATP was removed from ADP by the coupled assay system above. A solution containing 250 
mM impure ADP, three units each of yeast hexokinase and G6P-dehydrogenase, 10 mM 
magnesium acetate, 1 mM NADP, and 1 mM Glc was incubated for two hours at 24°C, and 
then filtered through a pressure concentrator with a molecular mass cut-off of 14 kDa. The 
purified ADP was stored frozen. 
Crystals of the quadruple mutant grew only by the second protocol (elevated G6P 
concentration). G6P was removed from crystals by soaking in G6P-free solutions. Crystals 
were transferred to 20% PEG 8000, 50 mM Mes (pH 6.5), 50 mM sodium acetate, 1 mM 
DTT, 40 mM magnesium acetate, 100 mM purified ADP, one unit of G6P-dehydrogenase, 
and NADP for five hours. The G6P-dehydrogenase/NADP guarantees the removal of any 
G6P that may be formed by the action of hexokinase on the ligand mixture. Data from these 
crystals appear in column 2 of Table 2. Glycerol was added to soaking solutions to a final 
concentration of 25% (v/v) prior to flash-freezing crystals in liquid nitrogen. 
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Data collection— X-ray diffraction data were collected from the crystal of Table 2, 
column 1, on the beamline of Dr Bartunik at Deutsches Elektronen Synchrotron (DESY), 
using a MAR CCD detector. The data from crystals of Table 2, column 2, were collected at 
BioCARS, Sector 14, at the Advanced Photon Source (APS), Argonne National Laboratory. 
Data were processed with programs Denzo/Scalepack (Otwinowski et al., 1993), 
DPS/Mosfilm (Steller et al., 1997) and Scala (Collaborative Computational Project, Number 
4, 1994). 
Structure determination and refinement— The crystal structure of the G6P/Glc 
monomer complex (Table 2, column 1) was determined by molecular replacement, using the 
subunit from G6P/Glc dimer complex (PDB entry 1HKB). The N and C-halves of 
hexokinase I were positioned independently in the unit cell. The program AmoRe (Navaza, 
1994) was used in calculation of rotation and translation functions, based on data to 4 Â, and 
then used again in the rigid-body refinement of the N and C-halves, against data to 3 À 
resolution (final rigid-body R-factor of 0.37). 
Model building and refinement— Refinement of the G6P/Glc monomer complex 
(Table 2, column 1) used ARP (Lamzin & Wilson, 1993), Refmac (Murshudov et al., 1997), 
programs from the CCP4 package, and parameters provided by Engh & Huber (1991). The 
refinement was monitored by the decline in Rfree, based on 5% of the data randomly culled 
from the refinement process. The protein molecule was split into its four domains, which 
were refined as rigid bodies. The program ARP, combined with Protin, Refmac, and Sigmaa, 
was used for restrained refinement and the calculation of electron density maps. Adjustments 
to the model were accomplished with XtalView (McRee, 1992) and O (Jones et al., 1991). 
The first 80% of water molecules were added automatically (3 a cut off applied to an F0bs-Fcaic 
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Fourier map) and refined with the solvent-building routine of ARP. Restrained refinement by 
Refmac with anisotropic scaling and minimization by the maximum likelihood method were 
used. The final 20% of water molecules were added manually and ambiguous areas were 
rebuilt using omit electron density maps produced with Refinac and Sigmaa. Data for the 
ADP/Glc-monomer complex (Table 2, column 2) were of modest resolution, making the use 
of ARP impractical. The model for the ADP/Glc complex reflects restrained refinement of 
individual parameters, but such refinement did not improve Rfree- The conformations of 
ligands and protein residues were verified by the comparison of electron density maps from 
two crystals, prepared independently by the same protocol. Generally, water molecules were 
fit to peaks of difference density maps higher than 3 a, only Lf the corresponding positions 
were occupied in the high-resolution structures of the G6P/Glc monomer complex. 
Exceptions to this rule were made in areas that had undergone a conformational 
change. The analysis of root-mean-square deviations in the positions of C atoms of different 
models employed the program LSQKAB of the CCP4 package. This program was also used 
to superimpose the glycerol kinase structure (Hurley et al., 1 993) onto the hexokinase I 
structures, and to determine the differences in the orientation of individual domains in 
hexokinase I structures. 
Data Bank accession numbers— Coordinates for the G6P/Glc and ADP/Glc 
monomer complex have been deposited in the RCSB Protein Data Bank under the accession 
labels 1CZA and 1DGK, respectively. 
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CHAPTER VI. GENERAL CONCLUSIONS 
The research included in this thesis contributes to our understanding of the regulation 
of human hexokinase I. Brain tissue depends heavily on glucose as an energy sourse. The 
reaction catalyzed by hexokinase I commits glucose to metabolism in brain cells. 
Chapter II proposes a mechanism of negative cooperativity in G6P binding and 
inhibition. Mutations in G6P binding sites in either the N- and C- terminal half of 
hexokinase I do not abolish G6P inhibition. However, the same mutations in the truncated 
hexokinase I (mini-hexokinase I) and mutations on both G6P binding sites abolish G6P 
inhibition completely. Hence, G6P binding sites, in the N- or C-domain, are functional in 
regulating hexokinase I. Combining results from isotope exchange by Fromm et al., which 
shows a G6P: hexokinase I steochiometry of 1, we propose negative cooperativity in G6P 
inhibition. Yet, the work in Chapter II does not answer whether one of the two G6P sites is 
dominant. 
Chapter III presents an allosteric mechanism of G6P inhibition. A comparison of 
hexokinase structures complexed with ADP/Glc and G6P/Glc reveal conformational changes 
in C-domain, implying the importance of the flexible subdomain in the C-half. The mutations 
in the base- and ribose-binding pocket of ATP in hexokinase I abolish G6P inhibition 
completely, while the same mutations do not affect G6P inhibition of mini-hexokinase. 
Obviously, the inhibition mechanisms for full-length and mini-hexokinase I are different. We 
assign the mechanism for mini-hexokinase I to be direct inhibition, and the mechanism for 
full-length hexokinase I to be allosteric. Presumably, G6P binding to N-domain of 
hexokinase I causes long-range conformational changes, which suppresses G6P binding to C-
domain. The molecular basis of the suppression needs to be investigated. 
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Chapter IV investigates the possible influence of dimerization observed in hexokinase 
I crystal structure. An interface mutant has been constructed and strudied by kinetics and 
small angle x-ray scattering. The interface mutant and wild-type hexokianse I possess 
essentially identical kinetic properties. The interface mutant has been proved to be 
monomeric by small angle x-ray scattering and crystallization. Monomeric hexokinase I was 
then used in small angle scattering experiments to investigate conformational changes under 
different ligation states. Structural models have been built to calculate the radius of gyrations 
of hexokinase I, and the calculated values were used to fit experimental data collected by 
small angle x-ray scattering. The results suggests a rod-like conformation of hexokinase I in 
different ligation states, implying only subtle conformational changes in hexokianse I are 
likely. In addition, the kinetic results show no evidence of dimerization in hexokinase 
regulation. 
Chapter V describes the crystal structures of monomeric hexokinase. For the first 
time the ATP binding site in C-domain of hexokinase I is revealed with high resolution. 
Comparisons of this structure with the hexokinase/G6P structure reveals conformational 
changes in hexokinase I under G6P and ATP states, and thus provides a molecular basis for 
G6P inhibition. Also, the allosteric interface between N- and C-domains of hexokinase I is 
implied by the current proposed mechanism of allosteric inhibition. The discovery of a 
nucleotide binding site in the N-domain introduces additional considerations regarding its 
function. 
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Perspectives for Future Research on Human Hexokinase 
There remain many questions regarding the regulation studies of hexokinase L If the 
allosteric mechanism is presumably dominant, then how is G6P binding to the C-domain 
suppressed? What structural elements are responsible for this suppression? The question may 
be answered by new crystal structures, electron paramagnetic resonance (EPR) and 
fluorescence studies. 
Studying the regulation mechanism of hexokinase I in vivo needs to be done as well. 
In human brain, hexokinase I binds to the mitochondrial outer membrane. The molecular 
interactions between hexokinase I and the mitochondrial permeability transition pore (PTP) 
provides another fertile field of research. The possible role (if any) that hexokinase I plays in 
regulating energy production and cell apoptosis are only two examples. Besides, the study of 
hexokinase I in association with mitochondria, another question waits to be answered: Why 
does nature keeps two functional G6P sites in hexokinase I? The retention of two functional 
sites may be related to cellular locations of hexokinase I in different tissue types. In red blood 
cells, hexokinase I is in the cytosol, thus it may be inhibited allostericly by G6P binding to 
N-domain. In brain tissue, hexokinase I is crowded at the contact sites, and presumably forms 
a tetramer. Under this condition, the conformational changes required in allosteric inhibition 
may not be available due to restraints of oligomerization. Hence, G6P may regulate 
hexokinase activity of mitochondrially associated enzyme by binding to active site. 
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